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Inositol Phospholipid and Tyrosine Phosphorylation Signaling in
the Biology of Hematopoietic Stem Cells

Amy L. Hazen

ABSTRACT

Blood cells are continuously produced throughout our lifetime by a rare
pluripotent cell that primarily resides in the adult bone marrow. This
hematopoietic stem cell (HSC) must maintain a careful balance between selfrenewal, differentiation and apoptosis in order to support hematopoiesis for such
a long duration. Understanding the mechanism of balance between these fates is
crucial to our understanding and clinical application of these cells.
From previous studies, we know Src homology 2 domain containing 5’
inositol phosphatase 1 (SHIP) plays an important role in HSC homeostasis and
function. Most interestingly SHIP impacts HSC homing to the bone marrow niche.
An ideal location and environment is essential for HSC to fulfill their physiological
roles. Here we present evidence that SHIP is expressed by cells of the HSC
niche. Furthermore, SHIP deficiency severely alters this environment and thus
damages HSC function.
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In addition to the extrinsic effects of a SHIP-deficient microenvironment on
HSC, there is an intrinsic requirement for SHIP expression in confining HSC to
the bone marrow niche. We previously demonstrated that lack of SHIP leads to
an increase in peripheral HSC. Here we demonstrate that SHIP-deficient HSC
from the spleen can provide radioprotection and sustained multi-lineage
repopulation in lethally irradiated hosts. This indicates extramedullary HSC can
function outside the traditional bone marrow niche in SHIP-deficient mice.
Combined, these studies indicate both extrinsic and intrinsic factors
contribute to HSC homeostasis and function. In order to better understand the
signaling pathways involved in self-renewal and differentiation, we applied an
array-based technology to hematopoietic cells at various levels of differentiation.
Comparing the phosphorylation signature, or ‘kinome’, of these cell types can
help pinpoint signaling mechanisms important for HSC self-renewal and lineage
commitment.

ix

Introduction

SHIP
Discovery of SHIP
Src homology (SH) 2 domain containing 5’ inositol phosphatase 1 (SHIP)
was first cloned in 1996 by five independent groups based on its ability to bind
the protein-tyrosine binding domain (PTB) of SH2-containing sequence protein
(Shc)1,2, the SH3 domain of growth factor receptor-bound protein 2 (Grb2)1,3, the
FcRIIB receptor4 and by gene trapping5. SHIP was initially observed as a
145kDa protein in human hematopoietic cell lines that became tyrosine
phosphorylated and associated with Shc after stimulation with erythropoietin
(Epo)6. Due to its broad expression in the hematopoietic compartment1-3,7, it
became important to determine SHIP’s role in hematopoiesis. Since its
identification in the mid-90’s its role in the hematopoietic system has undergone
extensive research.

Structure of SHIP
Structurally, SHIP contains an amino terminal SH2 domain, a 5’ inositol
phosphatase, two NPXY motifs and several polyproline rich domains (Figure 1).
Its primary role is believed to be the hydrolysis of the 5’ phosphate of
phosphatidylinositol-3,4,5-phosphate (PI(3,4,5)P3) and inositol-1,3,4,5–
1

tetrakisphosphate (I(1,3,4,5)P4)2,3,8. The hydrolysis of the 5’ phosphate of
PI(3,4,5)P3 gives SHIP the ability to oppose phosphatidyl inositol 3’ kinase
(PI3K) activity, thereby regulating a variety of cellular signaling pathways
important for proliferation, differentiation, apoptosis and migration.

Figure 1: Structural diagram of SHIP.
Full-length SH2 domain containing 5’ inositol phosphatase is a 145 kDa protein
primarily expressed in the hematopoietic system.

SH2 Domain
SHIP can bind to phosphorylated immunoreceptor tyrosine based
inhibition or activation motifs located in the tail of several receptors such as
FcRIIB on B cells, Ly49 receptors on natural killer cells, and FcRI on mast cells
4,9-11

via its SH2 domain, which has the potential to bind phosphotyrosines12,13.

The SH2 domain of SHIP also interacts with tyrosine phosphorylated Shp-214,15
and the Src kinase Lyn16. This latter interaction can stabilize SHIP near the
membrane and enhance its function. The SH2 domain of SHIP competes with
Grb2 for the phosphorylated tyrosine on Shc7. This competition for Shc inhibits its
interaction with Grb2 which in turn prevents the recruitment of a complex of
proteins that catalyze the activation of Ras and downstream mitogen-activated
2

protein kinase (MAPK) activation7. Thus SHIP can negatively regulate MAPK
activation by preventing the formation of this complex.

5’ Inositol Phosphatase
As evidenced by its ability to influence PI3K signaling in vivo3, SHIP has
an important role as an inositol phosphatase. The catalytic domain can hydrolyze
the 5’ phosphate from PI(3,4,5)P3 and I(1,3,4,5)P4 generating PI(3,4)P2 and
I(1,3,4)P3, respectively3,8,17. In contrast, PI3K can add a 3’ phosphate to
PI(4,5)P2 thereby generating more PI(3,4,5)P3. This careful balance of
enzymatic activity is needed to control the levels of PI(3,4,5)P3 in the cell, as it
plays a key role in the recruitment of pleckstrin homology (PH) domain containing
proteins such as Akt18-21.
Upon generation of PI(3,4,5)P3 in the plasma membrane, Akt translocates
to this site and becomes phosphorylated at Threonine 308 and Serine 473
resulting in its activation22,23. Phosphorylated Akt functions primarily to attenuate
the activation of the intrinsic apoptosis pathway by phosphorylation and
inactivation of pro-apoptotic proteins such as BAD24. In essence, by limiting
PI(3,4,5)P3 levels, SHIP can prevent the recruitment of effector molecules such
as Akt and negatively regulate downstream signaling of PI3K18-21,25. This
inhibition of Akt recruitment and activation leads to decreased proliferation and
survival signaling26,27. A recent study also described a C2 domain located at the
carboxyl end of SHIP’s phosphatase domain as an allosteric activation domain28.
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NPXY Motifs and PxxP Region
The carboxyl terminus of SHIP contains several NPXY motifs, where
NPXY indicates arginine (N) followed by proline (P) then any amino acid (X)
followed by a tyrosine (Y). Upon activation, these motifs are tyrosine
phosphorylated and become a binding site for PTB domain containing proteins
such as Shc29-31. These NPXY motifs can also directly bind the p85 subunit of
PI3K, indicating another potential role for SHIP in limiting PI3K signaling32-34.
Proline rich (PxxP) motifs are also found throughout the carboxyl terminus of
SHIP and allow interaction with SH3 domain containing proteins35. Importantly,
although SHIP can be phosphorylated, this does not appear to be required for its
5’ inositol phosphatase activity. This suggests that the location of SHIP at the
membrane, in proximity to target molecules, may play an equally important role
to phosphorylation in SHIP’s activation36.

SHIP Isoforms and Homolog
Full length SHIP is a 145kDa protein primarily expressed in the
hematopoietic compartment, however additional isoforms have been identified in
both mice and humans. In mice, the lower molecular weight 110, 124 and
135kDa isoforms are generated from the alternative splicing or proteolytic
cleavage at the carboxyl terminus of full-length SHIP1,4,37-40. Hematopoietic cell
lines frequently have expression of both the full-length 145kDa protein and a
135kDa SHIP isoform38, which results from the deletion of an internal PxxP motif
within the carboxyl terminus.
4

An additional 110kDa isoform was isolated from both mice and humans. In
lieu of a deletion in the carboxyl terminus, this isoform is missing the SH2
domain2,41. The human version lacks 214 amino acids at the amino terminus and
is named SIP-1102. Similarly, the homologous murine version lacks 260 amino
acids at the amino terminus resulting in the absence of the SH2 domain41. In
mice, the 110kDa isoform is expressed in embryonic and hematopoietic stem
cells from an internal promoter region within the intron between exons 5 and 6 of
the SHIP gene41,42. Interestingly, unlike full-length SHIP, this isoform is not
expressed in more differentiated hematopoietic cells and was therefore
designated stem cell restricted SHIP or s-SHIP. Although this work does not
examine the role of s-SHIP in the regulation of HSC, it should be noted that the
specific expression pattern of this isoform makes it important to these studies
and certainly warrants further investigation.
SH2 domain containing 5’ inositol phosphatase 2 (SHIP2) belongs to the
same class of inositol 5’ phosphatase proteins as SHIP1 and is its closest
relative43. It was first identified as inositol polyphosphate-like-protein 1 (INPPL1)44 but in 1997 was discovered by a separate group as a 150kDa protein with
38% amino acid homology to SHIP1 and was thereafter named SHIP245.
Although this sequence homology may not seem high, the majority of homology
is located within the functional domains of the proteins. The SH2 domains share
54% homology and the 5’ inositol phoshatase domains are 64% homologous45.
Similar to SHIP1, SHIP2 contains a PxxP region and an NPXY motif allowing
interactions with both SH3 and PTB domains. Despite their structural similarities
5

there are differences in expression and function, which at least partially
segregates their roles in signaling. SHIP2, a 150kDa protein, is encoded by an
entirely different gene. In fact, they are expressed from different chromosomes in
both mouse and human46, and although SHIP1 is primarily expressed in
hematopoietic cells, SHIP2 has a ubiquitous expression pattern45,47,48. Both can
dephosphorylate PI(3,4,5)P3, however SHIP2 can not hydrolyze I(3,4,5)P4.
Furthermore, studies have shown that SHIP1, not SHIP2, plays the dominant role
in controlling PI(3,4,5)P3 levels in response to activation in hematopoietic cells49.
Accordingly, studies in SHIP2-/- mice have indicated no hematopoietic
abnormalities. The dominant role of SHIP2 appears to be in modulating glucose
homeostasis50. However, the presence of SHIP2 cannot compensate for the lack
of SHIP1 in mice harboring a homozygous SHIP1 deletion. These SHIP1
deficient mice have severe hematological defects, making it safe to conclude
that, despite the structural homology between these proteins, they are not
functionally redundant.

PTEN
Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is a
ubiquitously expressed 54kDa inositol phosphatase that hydrolyzes the 3’
phosphate of PI(3,4,5)P3 generating PI(4,5)P251. Unlike SHIP, which needs
growth factor stimulation for activation, PTEN constitutively reduces the level of
PI(3,4,5)P3 in the cell and downregulates Akt activation51. When PTEN is
mutated, causing loss of function or inactivation, cell growth and apoptosis
6

signals become unregulated frequently resulting in cancer52. In fact, PTEN is a
potent tumor suppressor and one of the more commonly inactivated genes in
cancer53. Because PTEN constitutively acts to reduce basal PI(3,4,5)P3 levels,
its loss leads to such severe abnormalities that PTEN-/- mice are embryonic
lethal54.

SHIP Signaling
PI(3,4,5)P3 is a key second messenger in the PI3K pathway and plays a
central role in regulating many cellular functions. Low basal levels of PI(3,4,5)P3
in the cell are rapidly increased by PI3K upon stimulation. PI(3,4,5)P3 attracts PH
domain containing proteins to the membrane to mediate survival and/or
proliferation signaling55-57. Several inositol phophatases such as PTEN and SHIP
keep this activation in check. Ubiquitously expressed PTEN constitutively breaks
down PI(3,4,5)P3 levels and generates PI(4,5)P2, whereas SHIP requires
activation to reduce PI(3,4,5)P3 levels in hematopoietic cells51,57,58.
As mentioned earlier, SHIP was initially observed as a protein that
became tyrosine phosphorylated after stimulation of human hematopoietic cell
lines with Epo6. In fact, the stimulation of several growth factor and
immunological receptors leads to the recruitment of SHIP to the plasma
membrane where tyrosine phosphorylation occurs. This triggers the association
of SHIP with other signaling molecules, such as Grb214. (Figure 2) Growth factors
known to stimulate SHIP are granulocyte-macrophage-colony stimulating factor
(GM-CSF), granulocyte-CSF(G-CSF), stem cell factor (SCF), thrombopoietin
7

(TPO), Fms-like tyrosine kinase 3 ligand (Flt3L), interleukin-3 (IL-3), IL-4 and
importantly stromal cell derived factor-1 (SDF-1)7,32,59-68. Some immunological
receptors that recruit SHIP are the B cell receptor, the T cell receptor and the Fc
receptor4,69-74.
Interestingly, it appears that the membrane proximal location, not its
tyrosine phosphorylation, may be required for the primary inositol phosphatase
activity of SHIP3,75. The method of this translocation to the plasma membrane is
not completely understood and appears to have some variation dependent on the
cell type76. Once located at the membrane, the inositol phosphatase domain of
SHIP can reduce PI(3,4,5)P3 levels by generating PI(3,4)P2 and inhibit
downstream Akt activation. Additionally, this decrease in PI(3,4,5)P3 can lead to
a reduction in Btk membrane localization and activation. Inhibiting Btk activation
results in a subsequent decrease in PLC levels and an arrest of extracellular
calcium influx77,78. By dampening PI(3,4,5)P3 levels SHIP can also down regulate
NFB induced gene transcription in myeloid cells and inhibit the NFB pathway79.
At the membrane, the SH2 domain of SHIP preferentially binds to tyrosine
phosphorylated forms of Shc, among other adaptor proteins7. SHIP competes for
Shc interaction with Grb2 thereby inhibiting the formation of the multi-protein
complex between Shc, Grb2 and son of sevenless (SOS). Prevention of the
formation of this complex inhibits the activation of the MAPK pathway. Combined,
the roles of SHIP can influence survival, proliferation, and differentiation
signaling.
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Figure 2: Simplified schematic of signaling pathways influenced by SHIP.
Upon growth factor receptor engagement, SHIP is recruited to the membrane.
Once there SHIP can influence multiple signaling pathways. SHIP can hydrolyze
the 5’ phosphate of PIP3, opposing PI3K signaling. This inhibits the recruitment
of PH domain containing proteins such as Akt and inhibits downstream survival
signaling. SHIP can also reduce IP4 levels and limit differentiation signaling. By
binding Shc, SHIP inhibits the formation of a protein complex between Shc, Grb2
and Sos. This in turn inhibits downstream MAPK activation and proliferation
signaling.

9

SHIP Knockout Mouse Models
To better understand the function of SHIP, various groups have created
versions of the SHIP knockout (KO) mouse by deleting different portions of the
protein80-82. The study of these mouse models has provided a wealth of insight
into SHIP’s role in the hematopoietic compartment. Although viable, the SHIP KO
mice harbor profound abnormalities including: hyper-resorptive osteoclasts83,
reduced CD8 T cell numbers81, a disrupted NK cell repertoire11, hyperresponsive
mast cell degranulation84, increased myeloid cells in the bone marrow and
periphery60,81 and an increase in myeloid suppressor cells85. Interestingly, the
increase in myeloid suppressor cells combined with a promiscuous NK cell
repertoire mediates a significant decrease in graft-versus-host disease (GVHD)
and BM rejection, respectively after allogeneic bone marrow transplant11,85,86.
However, collectively the pathological effects of SHIP deficiency harbor
detrimental effects. The myeloproliferative disorder, causing expansion of
macrophages in the bone marrow and spleen, also results in infiltration and
consolidation of the lungs. This ultimately leads to the mouse’s death at 6 to 10
weeks of age81. Not surprisingly, SHIP-/- mice share phenotypic characteristics
with PTEN+/- mice87, suggesting that elevated levels of PI(3,4,5)P3 are the
primary cause of these characteristics.
Studies contained here within were completed using two mouse models of
SHIP deficiency. Both models were created by flanking the region to be deleted
with Cre recombinase recognition sites or loxP sites11. The promoter and the first
exon of the SHIP gene were floxed by homologous recombination in ES cells88.
10

The SHIPflox/flox animal is then crossed with a Cre transgenic animal, resulting in
the deletion of the targeted (or floxed) region. The Cre recombinase recognizes
the loxP sites and deletes the intervening DNA. This model deletes SHIP in the
entire animal generating mice with germline SHIP deficiency, indicated as SHIP-/mice11. However, this strategy also allows SHIP to be targeted for deletion in a
specific cell type or at a specific time depending on the promoter used to drive
Cre expression. The other model used here permits the inducible deletion of
SHIP at the time of our choice. Using our existing colony of SHIPflox/flox mice and
MxCre transgenic mice purchased from The Jackson Laboratory, we generated
MxCreSHIPflox/flox mice86. In these mice, the Cre recombinase is under control of
the Mx1 promoter, which is generally silent in healthy mice. However, upon
administering a series of polyinosinic-polycytidylic acid injections, interferon
levels can be elevated causing the Mx1 promoter to drive the expression of Cre
recombinase, which in turn results in the excision of the targeted SHIP sequence
flanked by loxP sites. These mice are indicated as MxCreSHIPflox/flox or SHIPdeleted mice.

Hematopoietic Stem Cells
Discovery of HSC
Despite our growing knowledge about stem cells, there is still no
universally acceptable definition for the term. Most attempts to define them are
made by assigning certain attributes; stem cells have the capacity to self-renew
as well as to produce a full range of differentiated progeny. Since we know an
11

adult vertebrate is made up of over 200 different cell types, the existence of stem
cells in embryogenesis seems intuitive. However, whether stem cells still persist
in the adult vertebrate is somewhat less obvious. Certainly, the male reproductive
organs continue to produce a large number of cells throughout life. Yet, upon
gross inspection, somatic tissues do not appear to be expanding during
adulthood. The most obvious evidence for the persistence of adult stem cells is
probably wound healing. Possibly the most crucial role for an adult stem cell is
the daily production of blood cells. Some blood cells, such as neutrophils and
platelets, may only survive for hours or days in the blood. Without the existence
of a hematopoietic stem cell (HSC) it would be impossible to support sustained
blood production throughout the vertebrate lifespan.
The first scientific evidence of a regenerative cell in the hematopoietic
system was shown in the 1940’s when shielding the spleen from radiation
allowed the survival of lethally irradiated animals89-91. Two years later studies
injecting bone marrow cells into irradiated animals yielded a similar result92. This
lead to the identification of a transplantable cell in the bone marrow, which could
prevent hematological failure after radiation93. We now know that cells obtained
from the bone marrow and cytokine-mobilized blood of healthy donors are useful
for transplantation. In the past ten years, HSC transplantation has evolved into a
common clinical practice. In order to improve the clinical efficacy of these
transplants, it is crucial to understand the biological functions necessary for HSC
to both self-renew and provide differentiated cells of the lymphoid and myeloid
lineages.
12

Development of the Hematopoietic System
The founding HSC originate during embryogenesis in a complex process
that involves multiple successive anatomical sites. Just after gastrulation the
hemangioblast gives rise to a subset of mesodermal precursors, which in turn
commit to becoming blood cells and embryonic hematopoiesis begins94. The first
precursors move to the yolk sac and begin to produce red blood cells. The yolk
sac provides initial transport from mother to fetus and is essential to murine
development95. Between E7.0 and 8.5 precursors in the yolk sac begin to
develop primitive erythrocytes, followed by primitive myeloid cells96. However, the
yolk sac microenvironment does not support full differentiation into definitive
lineages. Therefore these primitive cells must leave the yolk sac and seed the
fetal liver where they can complete terminal differentiation. Functional long-term
repopulating HSC (LT-HSC), which can provide sustained long-term
hematopoiesis, are not found until day E11.0 in the fetal liver. This indicates that
despite extensive production of progenitors, the yolk sac cannot support HSC
generation97. The primary hematopoietic organ during fetal development is the
fetal liver. It is the main site of HSC expansion and differentiation98. The fetal liver
microenvironment promotes self-renewing divisions of the HSC, rapidly
expanding the pool to a maximum plateau at E15.5 to 16.599. During this period,
a portion of HSC are relocated to the spleen, which can remain a site for
extramedullary hematopoiesis throughout adulthood. Skeletal development
begins at day E12.5 and functional HSC can be found in the bone marrow from
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E17.5 onwards100. However, HSC can be found in the circulation several days
before seeding the bone marrow. Indicating, a delay in colonization while the
bone marrow microenvironment forms100. Bone marrow stromal cells produce a
gradient of SDF-1 which attracts HSC, yet this chemokine appears to play little
role in the formation of the fetal liver HSC pool101. The switch from fetal liver to
bone marrow hematopoiesis is yet to be fully understood.
In addition to these concrete hematopoietic niches, a very small
percentage of HSC remain in circulation in both fetal and adult stages. In the
adult mouse approximately 100 HSC are in circulation during steady state
conditions102. The placenta also exhibits hematopoietic activity. In fact, HSC can
be found in the placenta (E10.5) before the circulation or fetal liver. This suggests
the placenta may be a source of de novo HSC. At day E12.5 there is a rapid
expansion of HSC in the placenta, indicating a microenvironment that supports
rapid self-renewal without differentiation103. The number of HSC in the placenta
rapidly decreases after E13.5 as the fetal liver pool begins to expand. It remains
to be shown whether the placenta supplies the major portion of HSC to the fetal
liver, however we know the fetal liver is directly downstream of the placenta in
circulation103.
Adding to the complexity of hematopoietic development, investigators
strongly argue a role for the aorta-gonad-mesonephros (AGM) region as a
second site of pre-fetal liver hematopoiesis104,105. Interestingly, the generation of
hematopoiesis in the yolk sac, placenta and AGM coincides with the
development of endothelial cells, which are a key component in supportive
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microenvironments106. In reality there are probably multiple independent origins
of HSC during fetal development.

Hematopoietic Hierarchy
HSC develop into differentiated blood cells via several lineage-restricted
pathways in distinct steps (Figure 3). Cells committed to lymphoid fates, such as
B cells, natural killer (NK) cells, T cells and dendritic cells develop through a
common lymphoid progenitor (CLP)107. This CLP is restricted to the production
of cells within the lymphoid lineage. Erythrocytes, granulocytes, macrophages,
and megakaryocytes are all derived from a common myeloid progenitor
(CMP)107, which similarly to the CLP is restricted to the formation of cells from the
myeloid arm. These progenitors have the ability to self-renew and create
differentiated blood cells, but because they are restricted to a single arm of
hematopoiesis they are considered “progenitors”, not stem cells. Once cells are
committed to myeloid differentiation, the CMP undergoes further commitment
steps to restrict its lineage potential to either a megakaryocyte and erythrocyte
progenitor (MEP) or a granulocyte and erythrocyte progenitor (GMP)108. This
hierarchy is a simplification of the intermediates involved in the differentiation
steps between HSC and mature blood cell.
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Figure 3: Schematic illustration of the hematopoietic hierarchy.
LT-HSC have near limitless self-renewal potential and can differentiate to
produce all the lineages of the blood. ST-HSC have reduced self-renewal
potential and can not sustain long-term multi-lineage hematopoiesis. Multi potent
progenitors (MPP) have limited self-renewal capacity. They can produce
downstream progenitors, which are restricted to the production of a specific
lineage. CLP and CMP are still considered progenitors as they can generate
multiple cell types, however they are restricted to the lymphoid or myeloid arms
of hematopoiesis. The CLP produces cells that are committed to lymphoid fates
such as B cells, NK cells, T cells and dendritic cells. The CMP produces both
GMP and MEP. GMP then give rise to granulocytes, monocytes and
macrophages, while MEP only give rise to red cells and platelets. Dendritic cells
can originate from either CL or CM progenitors.
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HSC Microenvironment
The shift between multiple anatomical sites during hematopoietic
development might permit different tissue microenvironments to alter HSC
priorities between expansion and quiescence. Fetal HSC are largely cycling,
however LT-HSC found in the adult bone marrow are primarily in G0 phase109.
The HSC microenvironment or “niche” appears to play an important role in
controlling this HSC homeostasis. Furthermore, proper migration to and seeding
of the anatomical locations most likely depends on the proper establishment of
the respective niches.
In 1978, Schofield first proposed the concept of a physiological
microenvironment that could support HSC homeostasis110. Recent studies have
established the niche as a complex tissue, encompassing multiple cell types that
work together to support hematopoiesis. The niche cells are in intimate contact
with HSC and produce many growth factors important in determining stem cell
fate, including leukemia inhibitory factor (LIF), IL-6, IL-8, SCF, and Flt3 ligand.
These cytokines are key regulators in the niche’s control of HSC self-renewal
and differentiation111-113. Specifically, a combination of TPO and Ftl3 ligand can
force limited HSC self-renewal114.
Stromal cell derived factor-1 (SDF-1), which is released from endothelialtype cells and osteoblasts within the bone marrow niche, appears to be required
for the HSC homing process. The CXCR4 receptor on the surface of HSC
induces migration towards an increasing SDF-1 gradient generated by stromal
cells in the niche115. In fact, the treatment of mice with an anti-CXCR4 antibody
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prior to transplantation results in failure of HSC engraftment, indicating this is a
critical interaction for proper BM homing116. Additional studies have established
that G-CSF, which is commonly used in clinic, mobilizes HSC to the peripheral
blood by decreasing SDF-1 levels and disrupting the homing signal117.
The players and mechanisms of the HSC microenvironment are complex
and have yet to be fully defined. These interactions must function in concert for
HSC to home to the bone marrow, remain in resting state in the niche, or
mobilize to the periphery when needed. An emerging body of evidence suggests
there are distinct microenvironments that regulate different HSC fates.
Many HSC in the BM reside near the endosteum, which is the inner
surface in the bone at the boundary of bone and marrow. The cells that line the
bone are heterogeneous, containing both osteoblasts and osteoclasts118. These
endosteal cells secrete a variety of factors that regulate HSC maintenance
including SCF, osteopontin, TPO, SDF-1, and angiopoietin117,119-123. In addition to
the secretion of soluble factors, proper HSC maintenance may also require cellto-cell contact with the endosteal surface. Osteoblasts express Jagged1, which
can activate Notch signaling in HSC124, indicating a direct contact interaction
between HSC and osteoblasts. N-cadherin is an adhesion molecule that was
believed to play a part in HSC lodgment at the endosteum, however, a recent
study showed N-cadherin deficient HSC had normal function in the niche125.
Additional work will be required to determine the importance of this cell contact
interaction compared to soluble factors excreted by the endosteal cells in
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regulating HSC. Regardless of the exact mechanism, the endosteal niche
appears to promote HSC quiescence and maintenance113,126,127.
During embryogenesis HSC are located in proximity to vasculature in the
yolk sac, AGM and placenta103,128. These blood vessels have a crucial role in
promoting the expansion of HSC throughout embryonic development and
probably still contribute during adult hematopoiesis. The spleen is frequently a
site of extramedullary hematopoiesis during adult life, indicating HSC can survive
away from the endosteal (or osteoblastic) niche. Most HSC in the spleen are
located near specialized blood vessels called sinusoids, implying extramedullary
HSC are supported by a sinusoidal (or vascular) niche. In 2005, Morrison’s group
used an elegant immunofluorescence study to show that many HSC in adult BM
were also found around sinusoids129. The concept of a vascular niche in the BM
is further supported by the observation that HSC can mobilize into the circulation
within minutes of administering IL-8130. The vascular niche is thus perceived to
support HSC mobilization or activation, however the evidence is merely
circumstantial. It remains to be determined if there are spatially distinct niches
with distinct functional roles in HSC regulation or if they both support similar HSC
function.
The histological complexity of the BM has made it challenging to pinpoint
the anatomical location of HSC in vivo. The immunohistological techniques used
by Morrison’s group do not allow for functional evaluation of the HSC within their
particular niches129. These in vitro studies are purely based on the phenotypic
characterization of the cells using combinations of surface receptors. Recent
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scientific advancements have been made using intra-vital microscopy to examine
HSC within their in vivo niches131,132. In these studies, osteoblasts and blood
vessels within the BM appear to be in very close proximity to one another and
intertwined with HSC. This co-localization demonstrates it is anatomically
improbable to have distinct osteoblastic and vasculaur niches in the BM131.
Regardless of how and where HSC are supported in the microenvironment,
normal niche function is required for regulated hematopoiesis.

HSC Functional Assays In Vivo
In order to establish HSC function, competitive repopulation models are
often used. This system directly models the donor and host competition for
hematopoietic engraftment in vivo133. After transplant donor cells home to the
marrow, engraft and differentiate into myeloid and lymphoid cells. However,
generating differentiated blood cells is not enough as most of these populations
are short-lived. The engrafted HSC must also maintain the pool of progenitors in
the host so that long-term hematopoiesis can be maintained. Short-term
precursors disappear 1-4 months after transplantation134, thereafter only longterm HSC (LT-HSC) will persist. Thus determination of donor repopulation after 4
months is essential in defining LT-HSC that can provide continuous
hematopoiesis for the duration of the lifespan of the host. Using the competitive
repopulating unit (CRU) assay, the function of LT-HSC is tested relative to
normally functioning competitor cells at 4 months post-transplantation. The donor
LT-HSC function is calculated using repopulating units (RU), where 1 RU
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represents the repopulating ability of 100,000 competitor cells133. Using RU to
determine the capacity of the donor HSC to repopulate host hematopoiesis, we
can operationally define a functional HSC.
In addition to the functional analysis of HSC, the research community has
invested much of its time in the phenotypic characterization of HSC using cell
surface markers. Defined monoclonal antibodies to these surface markers have
made it easier to isolate specific cell populations. It is important to note that there
remains much discussion between investigators in determining which
combination of surface markers most accurately isolates a pure LT-HSC
population. Using combinations of these cell surface markers, fluorescence
activated cell sorting (FACS) can be used to separate a purified LT-HSC
population from the bone marrow. Using sorted cells that express an HSC
phenotype, transplant competitions similar to the CRU assay can be performed
to directly test the functional capacity of these phenotypic HSC. In the direct
competition assay or DCA135, phenotypic LT-HSC from donors are transplanted
in competition with an equivalent dose of normal LT-HSC. Similar to the CRU
assay, stem cell function can be determined at 4 months post-transplant. The
DCA allows a more quantitative comparison of function on a per stem cell basis.

A Role For SHIP in HSC
The survival of an organism is dependent upon the ability of the HSC to
replenish the blood compartment throughout life. For proper hematopoiesis to be
sustained HSC must maintain a careful balance between self-renewal,
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differentiation and apoptosis. HSC homeostasis is yet to be fully understood but
we know HSC are at least in part regulated by extrinsic factors. Some of the
external cues that engage receptors on HSC are SCF, SDF-1, TPO, and
interleukins111-115. Several of these growth factors also stimulate PI(3,4,5)P3
formation by activating PI3K signaling. As previously described, SHIP plays a
prominent role in reducing PI(3,4,5)P3 levels in hematopoietic cells, therefore we
hypothesized SHIP might have a role in HSC homeostasis. Using SHIP knockout
mice, we determined SHIP-/- purified HSC or whole bone marrow (WBM) failed to
compete effectively with wild type (WT) HSC or WBM for long-term multi-lineage
hematopoietic repopulation (LTMR)136(Figure 4). This was determined using the
described DCA or CRU assays, respectively.
The failure of SHIP-/- HSC to provide LTMR, combined with a significant
expansion of phenotypic HSC numbers in SHIP-/- bone marrow and spleen
(Table 1) indicated a loss of HSC homeostasis with SHIP-deficiency. We then
determined the reduced LTMR function was not caused by accelerated
senescence, as there were significantly fewer apoptotic cells in SHIP-/- bone
marrow compared to WT. We hypothesized that a homing disruption might be
preventing SHIP-/- HSC from making it to the bone marrow niche after transplant,
thereby preventing proper LTMR. Using an in vivo homing assay, we determined
SHIP-/- HSC could not home to the bone marrow as well as WT HSC.
Appropriately, we also discovered several receptors key to the homing process
were significantly down regulated on the surface of SHIP-/- HSC (Figure 5).
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Combined, these results suggested a cell autonomous role for SHIP in HSC
homing and repopulation.
The capacity of HSC to home to the correct microenvironment is an
essential prerequisite for LTMR of transplanted hosts. Additionally, all LT-HSC in
adult bone marrow that engraft after transplant are in G0 phase109, whereas fetal
HSC are largely cycling, which indicates, HSC only perform their proper functions
when located within the appropriate niche. We therefore speculate that SHIPdeficiency might be disrupting the HSC niche and consequently lead to altered
HSC function, arguing a non-autonomous role for SHIP in HSC.
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Figure 4: SHIP-/- WBM and purified HSC have compromised reconstituting
activity.
(A) CRU activity calculated based on the percentage of global repopulation in the
PB by donor WBM cells 4 months after transplant. (B) Percentage of global
repopulation of PB by SHIP-/- or WT WBM cells 4 months after transplant. (C)
Percentage of lymphoid and myeloid PB cells derived from SHIP-/- or WT WBM
cells in the CRU assay 4 months after transplant. (D) Percentage of global
repopulation by purified HSC from SHIP-/- or WT BM 4 months after transplant.
(E) Percentage of lymphoid and myeloid PB cells derived from SHIP-/- or WT
purified HSC cells in the DCA assay 4 months after transplant. Significance was
established using the unpaired Student’s T test (*p<0.05). Errors shown
represent the SEM. [Black bars, cells derived from SHIP-/- BM; Grey bars, cells
derived from WT BM] This research was originally published in Blood. Caroline
Desponts, Amy L Hazen, Kim H T Paraiso and Wiliam G Kerr. SHIP deficiency
enhances HSC proliferation and survival but compromises homing and
repopulation. Blood. 2006; 107: 4338-4345. © the American Society of
Hematology.
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Table 1: Increased numbers of HSC cells in the BM and spleen of SHIP-/mice compared to WT littermates.
This research was originally published in Blood. Caroline Desponts, Amy L
Hazen, Kim H T Paraiso and William G Kerr. SHIP deficiency enhances HSC
proliferation and survival but compromises homing and repopulation. Blood.
2006; 107: 4338-4345. © the American Society of Hematology.
Population
Lin-Sca1+cKit+Thy1

low

Lin-cKit+Sca1+Flk2-

Lin-Sca1+cKit+CD48-

SHIP-/- ( % )

WT ( % )

P value

BM

0.4114 ± 0.0353

0.0725 ± 0.025

<0.0001

spleen

0.0957 ± 0.0131

0.0142 ± 0.0040

0.004

BM

0.2860 ± 0.0398

0.1340 ± 0.02015

0.0093

spleen

0.0827 ± 0.0141

0.027 ± 0.002

0.0172

BM

0.019 ± 0.002

0.0068 ± 0.0006

0.0012

spleen

0.0020 ± 0.0003

0.00023 ± 0.00005

0.0051

Figure 5: SHIP-/- HSC express lower levels of CXCR4.
(A) A representative histogram of CXCR4 expression on SHIP-/- or WT purified
HSC. (B) The median fluorescence intensity (MFI) of CXCR4 expression on
purified SHIP-/- or WT HSC. Significance was established using the unpaired
Student’s T test (*p<0.05). Errors shown represent the SEM. This research was
originally published in Blood. Caroline Desponts, Amy L Hazen, Kim H T Paraiso
and Wiliam G Kerr. SHIP deficiency enhances HSC proliferation and survival but
compromises homing and repopulation. Blood. 2006; 107: 4338-4345. © the
American Society of Hematology.
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SHIP is Required for a Functional Hematopoietic Stem Cell Niche

Abstract
SH2-domain-containing Inositol 5’-Phosphatase-1 (SHIP) deficiency
significantly increases the number of hematopoietic stem cells (HSC) present in
the bone marrow (BM). However, the reconstitution capacity of these HSC is
severely impaired suggesting that SHIP expression might be an intrinsic
requirement for HSC function. To further examine this question, we developed a
model in which SHIP expression is ablated in HSC while they are resident in a
SHIP-competent milieu. In this setting we find that long-term repopulation by
SHIP-deficient HSC is not compromised. Moreover, SHIP-deficient HSC from
this model repopulate at levels comparable to wild type (WT) HSC upon serial
transfer. However, when HSC from mice with systemic ablation of SHIP are
transplanted they are functionally compromised for repopulation. These findings
demonstrate SHIP is not an intrinsic requirement for HSC function, but rather that
SHIP is required for the BM milieu to support functionally competent HSC.
Consistent with these findings, cells that comprise the BM niche express SHIP
and SHIP-deficiency profoundly alters their function.
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Introduction
Because of their capacity for self-renewal and multi-lineage potential, HSC
support blood cell production throughout life. HSC are thought to reside in
specialized endosteal and vascular niches in the BM that support quiescence,
self-renewal and/or differentiation101,124,129,137. Other HSC fates include
mobilization to extramedullary sites and return to the BM102. Additionally,
apoptosis which regulates the homeostasis of differentiated tissues138,
contributes to control of the HSC compartment size, where ~1-2% of HSC are
apoptotic during steady-state hematopoiesis136. Thus, a careful balance between
the above fates must be maintained to sustain a sufficient number of HSC to
maintain blood cell production throughout life. We, and others, have found that
stem cell restricted SHIP (s-SHIP)41,139 and SHIP136,140 play roles in the biology of
pluripotent and adult tissue stem cells, respectively. Previously we showed that
SHIP limits the HSC compartment size in vivo. However, following
transplantation these HSC exhibit compromised BM homing and long-term multilineage repopulation136.
SHIP or s-SHIP expression in adult physiology has been documented in
HSC41,139, most blood cell lineages1,3,5,141, embryonic fibroblasts136 and
endothelial cells142. Through its enzymatic domain SHIP can hydrolyze the PI3K
products, PI(3,4,5)P3 and I(1,3,4,5)P4, and thus is capable of regulating the
activity of multiple PI3K effector pathways including the distal kinases Akt, Btk,
MAP/ERK, PLC- and intracellular calcium. The context in which SHIP mediates
these activities is determined by its expression, but also by its inducible
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recruitment to various receptor-associated signaling complexes mediated by
tyrosine phosphorylation of receptor motifs or NPXY sequences present in
SHIP1,3,143,144. Due to the nearly ubiquitous expression of SHIP in differentiated
hematopoietic cell types and its induced recruitment to a wide variety of receptorassociated signaling complexes, SHIP has the potential to regulate a wide variety
of cellular functions in adult physiology.
SHIP is expressed throughout the hematopoietic system and in
endothelial cells. From biochemical studies alone, it is difficult to determine if
SHIP might play a critical role in normal mammalian physiology. Towards this
end, genetic analysis of SHIP mutant mice has revealed a pivotal role for SHIP in
a variety of differentiated cell types. SHIP plays a role in the control of the NK
receptor repertoire and cytolytic function11,145, B cell development and antibody
production146,147, the myeloid response to bacterial mitogens148, development of
marginal zone macrophages82, osteoclast function83, lymph node recruitment of
dendritic cells85, mast cell degranulation149 and the homeostasis and function of
myeloid immunoregulatory cells85,86.
Previously we found that the poor repopulating capacity of SHIP-deficient
HSC may be a result of their reduced BM homing capacity. We speculated that
SHIP-deficient HSC might have normal repopulating function if they were not
required to home to their BM niche. To test this hypothesis, we developed an in
situ SHIP deletion model, where SHIP expression is ablated after HSC are
resident in a SHIP-competent BM microenvironment. Analysis of the
hematopoietic compartment in this model showed that SHIP-deficiency does not
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diminish the capacity of HSC to self-renew or mediate multi-lineage repopulation
after serial transfer to secondary hosts. Conversely, when SHIP expression is
ablated systemically in MxCreSHIPflox/flox mice, we find that SHIP-deficiency
compromises the repopulation potential of HSC in a similar fashion to that in
germline SHIP-deficient mice. This demonstrates an unanticipated requirement
for SHIP expression in the function of the HSC BM niche. Consistent with these
results we show SHIP is expressed in cells that comprise the BM niche and
SHIP-deficiency significantly alters their cell numbers, their production of
chemokines and their ability to support HSC cycling.

Results
HSC Rendered SHIP-deficient in a SHIP-competent Niche Retain Multilineage Repopulation
To determine if the repopulation defect observed for SHIP-/- HSC is due to
an inability to home efficiently to the BM HSC niche, we developed an in situ
SHIP deletion model where SHIP expression is ablated after achieving HSC
engraftment, bypassing the requirement of SHIP for BM homing. In this model,
we co-transplant an equal dose of SHIP-competent BM cells in which Cremediated deletion of SHIP is not possible. This model enables quantitation of
competitive repopulating activity (RU) for HSC rendered SHIP-deficient in situ. A
similar approach was previously used to study the role of Rho family proteins in
HSC function150. In our in situ SHIP deletion model, lethally irradiated
CD45.1+45.2+ recipients are transplanted with equal numbers of CD45.2+CD45.129

MxCreSHIPflox/flox and CD45.1+CD45.2- SHIP+/+ WBM cells. In these chimeras,
equivalent repopulation from both the MxCreSHIPflox/flox (CD45.2+CD45.1-) and
SHIP+/+ (CD45.1+CD45.2-) BM donors was observed at 60 days post-transplant,
indicating comparable levels of HSC engraftment from each donor (Figure 6). We
then administered three intra-peritoneal polyinosinic-polycytidylic acid (polyI:C)
injections to induce SHIP deletion in the MxCreSHIPflox/flox portion of these BM
chimeras. Two months after deletion, CD45.2+CD45.1- and CD45.1+CD45.2- cells
from the peripheral blood (PB) were FACS sorted to assess SHIP expression by
Western blot analysis. SHIP deletion is highly efficient in polyI:C-treated
MxCreSHIPflox/flox cells as indicated by the near complete absence of SHIP
expression in the CD45.2+CD45.1- cells derived from MxCreSHIPflox/flox HSC
(data not shown). For further confirmation, we harvested spleens from all
chimeras upon their termination 5 months post-transplant. Western blot analysis
of FACS sorted CD45.2+CD45.1- cells (Figure 7) confirmed nearly complete
ablation of SHIP expression in the hematopoietic compartment derived from
MxCreSHIPflox/flox HSC present in these BM chimeras.
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Figure 6: Equal engraftment by both donors after 60 days.
(A) Contour plots for CD45.1 vs. CD45.2 staining illustrating equal repopulation in
PB at 60 days post-transplant prior to polyI:C treatment in two representative
MxCreSHIPflox/flox(CD45.2):WT-Ly5.1(CD45.1) BM chimeras. (B) Percentage of
donor repopulation in the PB by MxCreSHIPflox/flox(CD45.2) and WTLy5.1(CD45.1) HSC in MxCreSHIPflox/flox(CD45.2):WT-Ly5.1(CD45.1) BM
chimeras at 60 days post-transplant prior to polyI:C treatment. Significance was
established using the unpaired Student’s T test. Errors shown represent the
SEM. [Black bars, cells derived from MxCreSHIPflox/flox BM; Grey bars, cells
derived from WT-Ly5.1 BM]
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Figure 7: SHIP can be deleted in situ after transplant.
Representative SHIP Western blot from single positive CD45.1+CD45.2- or
CD45.2+CD45.1- sorted cells isolated from splenocytes from
MxCreSHIPflox/flox(CD45.2):WT-Ly5.1(CD45.1) BM chimeras 5 months after
polyI:C treatment. Single positive splenocytes were sorted and lysate were
probed for SHIP expression.

At monthly intervals we monitored the degree of multi-lineage repopulation
by CD45.2+CD45.1- (SHIP-deficient) vs. CD45.1+CD45.2- (SHIP-competent) cells
in these chimeras. We found that SHIP-deleted HSC retain the ability to
efficiently perform long-term, multi-lineage repopulation at levels comparable to
the competing SHIP-competent HSC present in these chimeras. We observed no
significant difference in global hematopoietic repopulation (Figure 8A) or RU
activity (Figure 8B) between in situ SHIP-deleted and WT HSC up to 5 months
following ablation of SHIP expression. In addition, repopulation of both the
lymphoid and myeloid arms of hematopoiesis was observed out to 5 months
following induction of SHIP-deficiency (Figure 8C). Thus, when HSC are
established in situ and then rendered SHIP-deficient this does not significantly
compromise their potential for long-term, multi-lineage repopulation. However,
we did observe a small, but significant, reduction in T lymphocyte reconstitution
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in the CD45.2+CD45.1- SHIP-deficient compartment despite normal repopulation
of the B and NK lymphoid lineages (Figure 8D). Consistent with this finding, a
reduction in peripheral T cell numbers is observed in germline SHIP-/- mice81.
Because decreased T cell production is observed only in the SHIP-deficient
portion of these chimeras and not in the other lymphoid lineages, we conclude
that SHIP is required for the efficient development of T lymphocytes and this
requirement is intrinsic to the T cell lineage.
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Figure 8: In situ deletion of SHIP does not compromise the capacity of HSC
to mediate long-term multi-lineage repopulation.
(A) Percentage of global repopulation in the PB by MxCreSHIPflox/flox(CD45.2)
and WT-Ly5.1(CD45.1) HSC in MxCreSHIPflox/flox(CD45.2):WT-Ly5.1(CD45.1)
BM chimeras at the indicated times following polyI:C treatment (n5). At monthly
intervals, the level of donor reconstitution was assessed in PB. (B) Repopulating
Unit (RU) activity by MxCreSHIPflox/flox(CD45.2) and WT-Ly5.1(CD45.1) HSC in
the MxCreSHIPflox/flox(CD45.2):WT-Ly5.1(CD45.1) BM chimeras 5 months after
polyI:C treatment (n5). (C) Contour plots for CD45.1 vs. CD45.2 staining that
illustrate multi-lineage repopulation in PB 20 weeks after polyI:C treatment in a
representative MxCreSHIPflox/flox(CD45.2):WT-Ly5.1(CD45.1) BM chimera. (D)
Percentage repopulation of the indicated lymphoid and myeloid cell lineages by
MxCreSHIPflox/flox(CD45.2) and WT-Ly5.1(CD45.1) HSC in
MxCreSHIPflox/flox(CD45.2):WT-Ly5.1(CD45.1) BM chimeras 5 months after
polyI:C treatment (n5). At sacrifice, the level of donor reconstitution was
assessed in BM. Significance was established using the unpaired Student’s T
test (*p<0.05). Errors shown represent the SEM. [Black bars, cells derived from
MxCreSHIPflox/flox BM; Grey bars, cells derived from WT-Ly5.1 BM]
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SHIP-deficient HSC Derived from a SHIP-competent Niche Have Normal
self-renewal Capacity
Analysis of the above chimeras demonstrated long-term, multi-lineage
repopulation from the SHIP-deficient HSC compartment is intact when HSC are
resident in a SHIP-competent niche. This finding suggested that self-renewal
capacity might also be intact in SHIP-deficient HSC. To compare the self-renewal
capacity of SHIP-deficient and SHIP-competent HSC in these chimeras we
performed serial BM transfers from the initial chimeras to secondary recipients.
Whole BM was harvested from the chimeras described above at 5 months
following SHIP deletion and was then transplanted into lethally irradiated
CD45.1+CD45.2+ secondary hosts. Prior to these serial transfers we first
compared the proportion of SHIP-deficient (CD45.2+CD45.1-) to SHIP-competent
(CD45.1+CD45.2-) cells in the HSC compartment by multi-parameter flow
cytometric analysis of CD45.1 vs. CD45.2 staining on Kit+Lin-Sca1+CD48(KLSCD48) cells. This analysis revealed a statistically comparable level of
contribution to the KLSCD48 HSC compartment by the SHIP-deficient and SHIPcompetent HSC within the MxCreSHIPflox/flox:WT-Ly5.1 BM chimeras (Figure 9A).
SHIP-deficient HSC in these MxCreSHIPflox/flox :WT-Ly5.1 BM chimeras were also
found to represent a statistically comparable proportion of the KLSCD48
compartment as compared to SHIPflox/flox HSC in the SHIPflox/flox:WT-Ly5.1 BM
control chimeras analyzed in parallel (Figure 9B). We then monitored global
repopulation in the secondary hosts for a period of four months and found that
SHIP-deficient HSC from MxCreSHIPflox/flox:WT-Ly5.1 BM chimeras competed
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effectively in donor blood cell repopulation as compared to the WT-Ly5.1 HSC
present in the same BM inoculum (Figure 10), demonstrating that SHIP-deficient
HSC can effectively home and engraft upon transplant when they are derived
from a SHIP-competent HSC niche. Thus, SHIP expression is not an intrinsic
requirement for HSC homing to BM and self-renewal.

Figure 9: In situ deletion of SHIP does not compromise homing capacity of
HSC.
(A) Flow cytometric quantitation of the relative contribution to KLSCD48 HSC by
MxCreSHIPflox/flox(CD45.2) or WT-Ly5.1(CD45.1) cells in the BM of
MxCreSHIPflox/flox(CD45.2):WT-Ly5.1(CD45.1) chimeras 5 months after polyI:C
treatment (n3). BM cells were stained with markers for the Lineage-/lowcKit+Sca1+CD48- (KLSCD48) phenotype129. (B) Flow cytometric quantitation of the
relative contribution to KLSCD48 HSC by MxCreSHIPflox/flox(CD45.2) cells in the
BM of MxCreSHIPflox/flox(CD45.2):WT-Ly5.1(CD45.1) chimeras vs.
SHIPflox/flox(CD45.2) cells in SHIPflox/flox(CD45.2):WT-Ly5.1(CD45.1) control
chimeras. Both sets of chimeras were analyzed 5 months after polyI:C treatment
(n3). Significance was established using the unpaired Student’s T test. Errors
shown represent the SEM. [Black bars, cells derived from MxCreSHIPflox/flox BM
(Cre+); Grey bars, cells derived from WT-Ly5.1 BM (WT) or SHIPflox/flox (Cre-)]
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Figure 10: In situ deletion of SHIP does not compromise secondary
repopulating capacity of HSC.
Percentage global repopulation of PB at the indicated times by
MxCreSHIPflox/flox(CD45.2) and WT-Ly5.1(CD45.1) HSC after serial
transplantation of 1x106 WBM cells from MxCreSHIPflox/flox(CD45.2):WTLy5.1(CD45.1) chimeras 5 months after polyI:C treatment (n3). Significance
was established using the unpaired Student’s T test. Errors shown represent the
SEM. [Black bars, cells derived from MxCreSHIPflox/flox BM (Cre+); Grey bars,
cells derived from WT-Ly5.1 BM (WT)]

Systemic Induction of SHIP-deficiency in Adult Physiology is Detrimental to
the Repopulating Capacity of BM HSC
SHIP is expressed in embryonic, fetal and adult tissues, including
mesenchymal, endothelial and hematopoietic lineages3,41,139,141. Cells from all
three of these tissues participate directly or indirectly in the HSC BM niche and
thus their development may be impaired or altered during ontogeny in mice with
germline SHIP-deficiency. Therefore, the HSC disruptions we observe could be
due to developmental alterations of the niche by SHIP-deficiency. Alternatively,
SHIP could be required in adult physiology for the normal function of the niche.
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To test the latter possibility, we induced systemic SHIP-deficiency in adult mice
and then asked whether this also impairs HSC function. Induction of SHIPdeficiency in the previous chimeras showed no intrinsic requirement of SHIP for
BM homing, repopulation or self-renewal by HSC and thus, in the setting of
induced, but systemic SHIP-deficiency we are testing whether SHIP-deficiency
impairs the HSC niche in BM. For these studies, BM was harvested from
MxCreSHIPflox/flox mice that had undergone systemic SHIP-ablation by three
polyI:C injections (Figure 11). Induction of SHIP-deficiency was confirmed by
Western blot analysis of PBMC (data not shown).
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Figure 11: Schematic illustration of transplantation models.
(A) In Situ SHIP deletion BM transplants: MxCreSHIPflox/flox(CD45.2+) 5x105 WBM
cells were co-transplanted (i.v.) with 5x105 WBM competitor cells from WTLy5.1(CD45.1+) mice into lethally irradiated CD45.1+45.2+ recipients. After 60
days recipient mice were treated with three poly I:C injections to delete SHIP in
all cells derived from the MxCreSHIPflox/flox graft. (B) Systemic SHIP deletion BM
transplants: MxCreSHIPflox/flox(CD45.2+) mice were pre-treated with three poly I:C
injections to systemically delete SHIP. After SHIP deletion was confirmed, 5x105
WBM cells from MxCreSHIPflox/flox(CD45.2+) mice were co-transplanted (i.v.) with
5x105 WBM competitor cells from WT-Ly5.1(CD45.1+) mice into lethally irradiated
CD45.1+45.2+ recipients.
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Prior to transplant we observed that cells of the KLSCD48 HSC phenotype
were significantly expanded in mice with induced SHIP-deficiency relative to
SHIPflox/flox controls that underwent an equivalent regimen of polyI:C injections
(Figure 12). Furthermore, the absolute number of KLSCD48 cells in mice with
induced SHIP-deficiency was significantly expanded compared to SHIPflox/flox
controls (data not shown). This expansion seems to be restricted to more
primitive KLSCD48 and KLS progenitor cells and was not found in cKit+Lineagecells (data not shown). Because we observed no significant expansion of the
SHIP-deficient KLSCD48 cells in chimeras with a SHIP-competent niche (Figure
9), we conclude then that SHIP expression is required by the adult BM niche to
limit the size of the KLSCD48 HSC compartment. To analyze the repopulating
ability of BM HSC in mice with systemic induction of SHIP deficiency, we cotransplanted equal numbers of WBM cells from SHIP-deleted (CD45.2+CD45.1-)
and SHIP-competent (CD45.1+CD45.2-) donors into lethally irradiated WT
(CD45.2+CD45.1+) recipients. As before, monthly peripheral blood monitoring
was used to assess engraftment. Using both global repopulation (Figure 13A)
and RU (Figure 13B) as measures of engraftment, the HSC from donors with
induced SHIP-deficiency did not compete effectively against HSC from SHIPcompetent donors.
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Figure 12: Systemic induction of SHIP-deficiency compromises
homeostasis of the HSC compartment.
Flow cytometric quantitation of KLSCD48 HSC in the BM of
MxCreSHIPflox/flox(CD45.2) mice and SHIPflox/flox(CD45.2) controls 21 days after
polyI:C treatment (n3). Significance was established using the unpaired
Student’s T test (*p<0.05). Errors shown represent the SEM. [Black bars, cells
derived from MxCreSHIPflox/flox BM; Grey bars, cells derived from SHIPflox/flox]

Figure 13: Systemic induction of SHIP-deficiency compromises the
capacity of HSC to mediate repopulation over time.
(A) Percentage of global repopulation in PB at the indicated times post-transplant
by WBM cells from SHIP-ablated MxCreSHIPflox/flox(CD45.2) donors and WTLy5.1(CD45.1) control donors (n9). (B) Repopulation Unit (RU) activity from
SHIP-ablated MxCreSHIPflox/flox(CD45.2) donors and WT-Ly5.1(CD45.1) control
donors (n9). Significance was established using the unpaired Student’s T test
(**p<0.005; ***p<0.0001). Errors shown represent the SEM. [Black bars, cells
derived from MxCreSHIPflox/flox BM; Grey bars, cells derived from WT-Ly5.1 BM]
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Furthermore, multi-lineage reconstitution appears to be significantly
compromised for all lymphoid lineages in the PB (Figure 14A-B) and in myeloerythroid lineages in the BM (Figure 14C). However, despite significantly
decreased myelopoiesis, megakaryopoiesis and erythropoiesis in the BM by
HSC from mice with induced SHIP-deficiency (Figure 14C), we observed
statistically comparable myeloid reconstitution in the peripheral blood and spleen
from these HSC (Figure 14B and data not shown). This sustained peripheral
myelopoiesis by the SHIP-deficient BM graft that occurs in spite of significantly
compromised central myelopoiesis is likely due to robust extramedullary
myelopoiesis that we and others observe in the spleens of SHIP-/- mice81.
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Figure 14: Systemic induction of SHIP-deficiency compromises the
capacity of HSC to mediate long-term multi-lineage repopulation.
(A) Representative dual color contour plots that illustrate the level of PB
reconstitution at 24 weeks post-transplant from SHIP-ablated
MxCreSHIPflox/flox(CD45.2) BM donors and WT-Ly5.1(CD45.1) BM competitor
donors. (B) Percentage PB repopulation for the indicated lymphoid or myeloid
lineage by WBM cells in a competitive transplant of SHIP-ablated
MxCreSHIPflox/flox(CD45.2) and WT-Ly5.1(CD45.1) BM competitor cells (n9).
Prior to sacrifice, the level of donor reconstitution was assessed in PB. (C)
Percentage BM repopulation for the indicated myeloid (Mac1), granulocytic (Gr1),
megakaryocytic (CD41) or erythroid (Ter119) lineage by WBM cells in a
competitive transplant of SHIP-ablated MxCreSHIPflox/flox(CD45.2) and WTLy5.1(CD45.1) BM competitor cells (n9). At sacrifice, the level of donor
reconstitution was assessed in BM. Significance was established using the
unpaired Student’s T test (*p<0.05; ***p<0.0001). Errors shown represent the
SEM. [Black bars, cells derived from MxCreSHIPflox/flox BM; Grey bars, cells
derived from WT-Ly5.1 BM]
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A SHIP-deficient BM Microenvironment Expands Phenotypic HSC and
Reduces Surface Expression of CXCR4
Expansion of the phenotypic HSC compartment and functional impairment
of HSC in mice following the induction of systemic SHIP-deficiency described
above was reminiscent of our previous findings for HSC in germline SHIP-/- mice.
To examine whether CXCR4 surface expression on HSC might also be altered
by the SHIP status of the BM niche, we assessed CXCR4 surface expression on
in situ SHIP-deleted HSC where the niche remains SHIP-competent and in HSC
from mice following induction of systemic SHIP-deficiency where the BM
microenvironment is also rendered SHIP-deficient. In the in situ SHIP-deleted
model described in Figures 6-9, we found that the SHIP-deficient KLSCD48 cells
do not show significant reductions in CXCR4 surface expression as compared to
SHIP-competent KLSCD48 cells present in the same mice (Figure 15A-B).
However, when we analyzed the surface expression of CXCR4 on
KLSCD48 cells in mice with induced systemic SHIP-deficiency, we found that the
CXCR4 surface expression is significantly reduced relative to SHIPflox/flox controls
that received an equivalent regimen of polyI:C (Figure 16A-B). As shown in
Figure 12, KLSCD48 cells are also significantly expanded in mice when systemic
SHIP-deficiency is induced. Thus, expansion of the phenotypic HSC
compartment and down-modulation of CXCR4 are triggered only by induced,
systemic SHIP-deficiency, demonstrating regulation of these HSC properties by
the BM niche in adult physiology.
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Figure 15: In situ deletion of SHIP does not alter CXCR4 surface expression
on KLSCD48 HSC.
(A) A representative histogram of CXCR4 surface expression on KLSCD48 HSC
cells derived from MxCreSHIPflox/flox(CD45.2) or WT-Ly5.1(CD45.1) donors in the
BM of MxCreSHIPflox/flox(CD45.2):WT-Ly5.1(CD45.1) chimeras 5 months after
polyI:C treatment. (B) Median Fluorescence Intensity (MFI) of CXCR4 staining on
KLSCD48 HSC cells derived from MxCreSHIPflox/flox(CD45.2) or WTLy5.1(CD45.1) donors in the BM of MxCreSHIPflox/flox(CD45.2):WT-Ly5.1(CD45.1)
chimeras 5 months after polyI:C treatment. [Black boxes, cells derived from
MxCreSHIPflox/flox BM (Cre+); Grey boxes, cells derived from WT-Ly5.1 BM (WT)]

Figure 16: Systemic deletion of SHIP significantly impairs CXCR4 surface
expression on KLSCD48 HSC.
(A) Representative histograms of CXCR4 surface expression on KLSCD48 HSC
in the BM of MxCreSHIPflox/flox(CD45.2) mice or SHIPflox/flox(CD45.2) controls 21
days after polyI:C treatment. (B) MFI of CXCR4 staining on KLSCD48 HSC in the
BM of MxCreSHIPflox/flox(CD45.2) or SHIPflox/flox(CD45.2) controls 21 days after
polyI:C treatment. Significance was established using the unpaired Student’s T
test (*p<0.05). [Black boxes, cells derived from MxCreSHIPflox/flox BM (Cre+);
Grey boxes, cells derived from SHIPflox/flox (Cre-)]
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Production of Soluble Factors that Influence HSC Behavior are Altered in
SHIP-deficient Mice
Although the BM niche can influence the behavior of HSC by elaborating
cell bound ligands for HSC receptors, it also mediates effects through the
production of soluble factors that influence HSC proliferation, survival,
mobilization, and BM homing. Consistent with our proposed disruption of niche
function by SHIP-deficiency, SHIP-/- mice exhibit significantly increased plasma
levels of several growth and survival factors for HSC (TPO, G-CSF, IL-6) (Table
2). The increase in these factors and others may contribute to the increased
number of HSC present in both the medullary and extramedullary compartments
of SHIP-/- mice. We also observe increased concentrations of soluble factors that
promote HSC mobilization, including G-CSF, IL-5 (Table 2), MMP-9 (Figure 17A)
and soluble VCAM-1 (Figure 17B).
In addition, homing and retention of HSC by the SHIP-deficient BM niche
may be compromised by reduced production of SDF-1/CXCL12. We find
significantly reduced SDF-1/CXCL12 in both the blood and BM plasma of SHIPdeficient mice (Figure 18A-B). SDF-1/CXCL12 is produced by both the
osteoblastic and vascular niche in BM101,117. In fact, decreased SDF-1 production
in the SHIP-deficient BM niche could be triggered by increased G-CSF
production, as G-CSF is known to reduce SDF-1 expression in BM niche cells151.
Taken together, these findings provide evidence for several significant
perturbations in the SHIP-deficient BM niche.
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Table 2: Disrupted cytokine distribution in peripheral blood of SHIPdeficient mice.
Various factors were measured in serum obtained from PB by ELISA. The data is
pooled from multiple assays derived from at least 4 different plasma samples for
each genotype. Significance was established using the unpaired Student’s T
test.

Cytokine

SHIP -/-

(SEM,N)

WT

(SEM,N)

P value

TPO (ng/ml)

13.36

(± 0.3636, N=11)

11.79

(± 0.2143, N=14)

0.0007

G-CSF (pg/ml)

749.1

(± 39.13, N=4)

161.9

(± 24.62, N=4)

<0.0001

IL-6 (pg/ml)

39.82

(± 6.201, N=11)

13.67

(± 0.5205, N=13)

0.0001

IL-5 (ng/ml)

0.2147

(± 0.02350, N=11)

0.1511

(± 0.01634, N=14)

0.0314
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Figure 17: SHIP-deficiency alters production of HSC mobilization factors.
(A) Scatter plots indicating the mean and range for the concentration of MMP-9 in
the blood plasma of SHIP-/- and WT littermates. (B) Scatter plots indicating the
mean and range for the concentration of VCAM-1 in the blood plasma of SHIP-/and WT littermates. The data is pooled from multiple assays derived from a
minimum of 7 different samples for each genotype. Significance was established
using the unpaired Student’s T test (***p<0.0001). [Black boxes, SHIP-/samples; Grey boxes, WT samples].

Figure 18: SHIP-deficiency alters production of HSC homing factors.
(A) Scatter plots indicating the mean and range for the concentration of SDF1/CXCL12 in the blood plasma of SHIP-/- and WT littermates. (B) Scatter plots
indicating the mean and range for the concentration of SDF-1/CXCL12 in the BM
plasma of SHIP-/- and WT littermates. The data is pooled from multiple assays
derived from a minimum of 7 different samples for each genotype. Significance
was established using the unpaired Student’s T test (**p<0.005; ***p<0.0001).
[Black boxes, SHIP-/- samples; Grey boxes, WT samples].
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A Role for SHIP in BM Microenvironment Signaling and Function
Our transplantation studies, described above, indicated SHIP deficiency
disrupts the BM niche that supports normal HSC function and BM homing. SHIP
is expressed primarily in hematopoietic tissues in both humans and mice;
however, direct analysis of SHIP expression in cells that constitute BM niche cell
types was not directly tested1,3,5,141,152. We sought more direct evidence of a role
for SHIP in the BM microenvironment by assessing whether it is expressed in
cells that constitute key non-hematopoietic cell types in the BM niche. Thus, we
prepared osteoblast (OB) and stromal cell cultures from SHIP-/- and WT BM.
There were no substantive differences in morphology of stromal cells between
the two genotypes. However, in OB cultures we consistently observe readily
apparent differences with SHIP-/- OB exhibiting elongated and non-randomly
oriented protrusions (Figure 19: day 11) and organized growth along axes
(Figure 19: days 13 and 23).
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Figure 19: SHIP-/- OB cultures exhibit elongated and non-randomly oriented
protrusions and organized growth along axes.
Representative OB cells propagated from SHIP-/- and WT femurs after 11, 13,
and 23 days in culture. All images were generated using a Nikon TE2000
inverted microscope with a 10x 0.25NA PlanFluor objective lens and a Retiga
1300 12bit CCD QImaging camera. The images were acquired using IP Lab v3.6
software (Scanalytics of BD Biosciences).
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We readily detect SHIP protein expression in WT stromal (Figure 20A)
and OB cultures (Figure 20B). In addition, we detect tyrosine phosphorylation of
SHIP in WT BM stromal cells indicating SHIP participates in signaling pathways
active in cells of the BM niche (Figure 20C). Consistent with our detection of
SHIP expression in BM niche cell cultures, we confirmed that SHIP protein
expression is also readily detected in stromal cultures derived from the BM of
SHIPflox/flox mice but not MxCreSHIPflox/flox mice treated with polyI:C (Figure 20D).
These results indicate SHIP is expressed and participates in signaling in BM
niche cells and thus is capable of influencing their function.
A lack of hematopoietic lineage markers combined with positive selection
of vascular cell adhesion molecule-1 (VCAM1) is used to delineate mesenchymal
stem/progenitor cells and endothelial cells in the BM microenvironment153-155. We
find significantly more VCAM1+Lin- cells in the BM of mice with germline or
induced SHIP deficiency, relative to their SHIP competent counterparts (Figure
21A-B). Thus, SHIP expression is required for the homeostasis of stromal cells
in the BM compartment during adult physiology.
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Figure 20: SHIP is expressed and phosphorylated in BM niche cells.
(A) Representative SHIP Western blot from stromal cells cultured from the BM of
SHIP-/- and WT littermates. (B) SHIP Western blot from osteoblast cells cultured
from the BM of SHIP-/- and WT littermates. (C) pTyr Western blot on a SHIP
immunoprecipitation of stromal cells cultured from the BM of SHIP-/- and WT
littermates. (D) SHIP Western blot from stromal cells cultured from the BM of
MxCreSHIPflox/flox and SHIPflox/flox littermates. Each lane on the Western blots
represents a culture lysate derived from an independent mouse.
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Figure 21: SHIP defficency alters cell numbers in the BM niche.
(A) Scatter plots indicating the mean and range of VCAM1+Lin- cells present in
the BM of SHIP-/- and WT (Germline) or MxCreSHIPflox/flox and SHIPflox/flox (MxCre)
littermates as indicated. (B) Dual color contour plots illustrating the VCAM+Lincells present in the BM of SHIP-/- and WT (LEFT) or polyI:C treated
MxCreSHIPflox/flox and SHIPflox/flox littermates (RIGHT). Significance was
established using the unpaired Student’s T test (*p<0.05; **p<0.005;
***p<0.0001). [Black boxes, SHIP-/- samples (A, LEFT) or MxCreSHIPflox/flox
samples (A, RIGHT); Grey boxes, WT samples (A, LEFT) or SHIPflox/flox samples
(A, RIGHT)].
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To further assess a functional role for SHIP in the BM microenvironment,
we assayed SHIP-/- and WT OB for alkaline phosphatase (ALP) activity. SHIPdeficient OB exhibit significantly less ALP activity compared to WT OB (Figure
22A-B), indicating they are immature as ALP activity is closely correlated with
maturation in the OB lineage156-159. As a further test of SHIP-deficient BM niche
function, we examined the cell cycle kinetics of WT hematopoietic
stem/progenitor cells (HS/PC) placed on BM stromal layers prepared from either
SHIP-/- or WT mice. When we place 1 million HS/PC in co-culture with confluent
SHIP-/- stromal layers and measure proliferation by loss of CFSE, we find a clear
defect in the ability of SHIP-/- BM stroma to support normal proliferation of WT
HS/PC (Figure 23C-D). These results demonstrate a significant and qualitative
change in BM stromal cells that lack SHIP expression such that they are unable
to support normal proliferation by SHIP-competent HS/PC.
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Figure 22: SHIP-deficiency alters the function of osteoblasts from the BM
niche.
(A) Alkaline phosphatase positive cells from cultures of SHIP-/- and WT
osteoblasts showing altered phosphatase kinetics at 1 minute, 15 minutes, and
30 minutes. (B) Representative FACS plots illustrating gating strategy for ALP
positive cells based on ALP negative BM controls and showing ALP kinetics at
increasing time points. Significance was established using the unpaired Student’s
T test (**p<0.005; ***p<0.0001). [Black, SHIP-/- osteoblasts(A); Grey, WT
osteoblasts(A)].
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Figure 23: SHIP-deficiency alters the ability of stromal cells from the BM
niche to support normal HSC function.
(A) Frequency of Lin-cKit+Flk2- (KFL) stem/progenitor cells among Lin-depleted
BM cells (HPC) cultured alone (White), or with SHIP-/- (Black) or WT (Grey)
stromal cells in each cell division after 36hrs. (B) Representative histograms
showing decreased proliferation of CFSE+ KFL cells cultured with SHIP-/- stromal
cells (TOP) as compared to those cultured with WT stromal cells (BOTTOM).
Significance was established using the unpaired Student’s T test (*p<0.05;
**p<0.005; ***p<0.0001). [White, WT HPC alone(A); Black, HPC cultured with
SHIP-/- stroma(A); Grey, HPC cultured with WT stroma(A)].

56

Additionally, we analyzed the supernatants of multiple independent SHIPdeficient and WT stromal cultures for SDF-1 production and found profoundly
compromised SDF-1 production in all SHIP-deficient cultures analyzed as
compared to WT cultures analyzed in parallel (Figure 24A). Consistent with this,
we saw a similar defect in SDF-1 production by stromal cells derived from
MxCreSHIPflox/flox mice as compared to SHIPflox/flox controls (Figure 24B). Thus,
SDF-1 production by BM niche cells is significantly impaired by SHIP-deficiency.
As SDF-1 is pivotal for BM homing and retention of HSC, the impaired production
of SDF-1 by SHIP-/- stroma is consistent with increased peripheralization of HSC
to the blood and spleen of SHIP-/- mice136. Accordingly, immunohistology on
femur sections from SHIP-/- mice show little to no SDF-1 present in the BM
(Figure 25ii). In fact, levels appear to be similar to those in isotype control
sections (Figure 25iii) indicating an almost complete lack of SDF-1 in SHIPdeficient BM. When taken together these results demonstrate that SHIP is
required for multiple functions of BM niche cells, including production of factors
that mediate BM recruitment, HSC retention and HSC proliferation.
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Figure 24: SHIP-deficiency alters cytokine production by cells from BM
niche.
(A) Scatter plots indicating the mean and range for the concentration of SDF1/CXCL12 in the cell culture supernatant of SHIP-/- and WT BM stromal cells. (B)
Scatter plots indicating the mean and range for the concentration of SDF1/CXCL12 in the cell culture supernatant of MxCreSHIPflox/flox and SHIPflox/flox BM
stromal cells from polyI:C treated mice. Results are representative of
independent stromal cultures derived from independent mice. Significance was
established using the unpaired Student’s T test (**p<0.005; ***p<0.0001). [Black,
SHIP-/- samples(A); Grey, WT samples(A); Black, MxCreSHIPflox/flox samples(B);
Grey, SHIPflox/flox samples(B)].

Figure 25: SHIP-deficiency ablates in vivo SDF-1 production in the BM
niche.
Representative photomicrographs (63X) of frozen sections prepared from adult
femurs of WT (i) and SHIP-/- mice (ii) that were stained with biotinylated mouse
anti-SDF-1 Ab (i, ii) or a biotinylated mouse IgG1k control antibody (iii). Staining
by the anti-SDF-1 or the IgG1k control was revealed by a secondary stain of SAAlexaFluor 546. The background SDF-1 staining observed with SHIP-/- BM
sections was consistently comparable to staining observed in isotype control
stains performed on both SHIP-/- and WT femurs (iii and data not shown).
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Discussion
In this study we show that induction of SHIP deficiency in the adult
compromises HSC function only when SHIP-deficiency is systemic, indicating a
requirement for SHIP expression by the HSC niche. In fact, when adult HSC
residing in a SHIP-competent niche are rendered SHIP-deficient, they completely
retain their capacity for multi-lineage repopulation and self-renewal. Thus, SHIP
expression is not an intrinsic requirement for control of HSC homeostasis or
function in the BM, but is required for normal function by the BM niche.
Consistent with this, we find that SHIP is expressed and tyrosine phosporylated
in niche cells and plays an intrinsic role in their production of chemokines,
homeostasis and function. Furthermore, we find that following induction of
systemic SHIP-deficiency in the adult, the SHIP-deficient BM microenvironment
promotes expansion of cells of the KLSCD48 HSC phenotype. Despite this
phenotypic expansion, BM HSC from these donors are fundamentally altered
such that they are no longer able to mediate efficient multi-lineage repopulation
following intravenous transplantation.
We find that three polyI:C injections results in highly efficient SHIP
deletion in MxCreSHIPflox/flox cells. In the event that a small percentage of cells in
the in situ deletion chimeras remained SHIP-competent and repopulated as well
as their WT counterparts in the serial transplants shown in Figure 10, then it also
logically follows that we should observe comparable repopulation with BM from
systemically deleted MxCreSHIPflox/flox mice (Figure 13). On the contrary, we
observe significantly compromised repopulation by this SHIP-deficient graft
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despite the potential presence of residual SHIP-competent cells. These data
combined with robust SHIP deletion in splenocytes (Figure 7) in the in situ
deletion model strongly suggest that normal repopulation by in situ SHIP deleted
HSC is not due to residual, undeleted HSC clones.
Our findings demonstrate the HSC BM niche is profoundly altered by
SHIP-deficiency. SHIP expression has previously been documented in primary
fibroblasts and endothelial cells, indicating the potential for SHIP to regulate the
activity of these cell types139,142. Here we document that SHIP is expressed in OB
and stromal cells derived from the BM niche. SHIP has previously been
implicated in the regulation of osteoclast function and their resorption of
osteoblasts83. However, SHIP expression in primary osteoclasts has not been
demonstrated, suggesting the possibility that accelerated bone resorption
exhibited by SHIP-/- osteoclasts could be caused by some of the cytokine
alterations that we observe in SHIP-/- mice.
The immature state of SHIP-/- OB is consistent with the deregulated cell
cycle kinetics and repopulation defect we previously reported for SHIP-/- HSC as
mature OB are required to maintain HSC in a quiescent state160-163 in which their
reconstituting potential is maximal109,162-164. Consistent with this functional OB
impairment, we see a significant expansion of the VCAM1+Lin- niche in SHIP-/mice, yet a functional defect in their ability to support normal HSC cycling,
indicating an inability to support normal HSC function in a SHIP-deficient niche.
A previous report found that VEGF-A can induce SHIP expression in
endothelial cells142, and thus SHIP expression, or function, could be induced in
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niche cells to limit effector functions of BM niche cells. This could include SHIP
regulating the production of key factors produced by the niche, including G-CSF,
TPO, IL-5 and SDF-1. Consistent with this, we observe increased levels of GCSF, TPO, IL-6 and MMP-9, and decreased SDF-1/CXCL12 in the plasma of
SHIP-deficient mice. Furthermore, we show direct evidence of compromised
SDF-1 production by SHIP-deficient BM niche cells. This likely contributes to the
profound mobilization and peripheralization of phenotypic HSC that we previously
observed in SHIP-deficient mice. It has not escaped our attention that increased
G-CSF production by SHIP-deficient microenvironment cells could in turn downregulate SDF-1 production by other microenvironment cells. This would cause
HSC mobilization while simultaneously reducing HSC recruitment to niche cells
such as OB that maintain HSC quiescence.
The cellular and molecular pathways in the BM microenvironment altered
by SHIP-deficiency remain to be defined. Nonetheless, these findings are the first
to implicate inositol phospholipid-signaling pathways as being critical to the
function of the BM microenvironment that supports HSC function. It remains to be
determined whether other members of phosphoinositide signaling pathways also
impact niche function or whether they have an impact solely through intrinsic
effects in HSC. The analysis of PTEN-deficient mice suggests PTEN plays an
intrinsic role in the control of HSC homeostasis and function165,166. Thus, PTEN is
likely the dominant inositol phosphatase that opposes effector pathways distal to
PI3K in HSC, while SHIP appears to be a dominant inositol phosphatase in cells
of the BM niche that support HSC. It will be intriguing to determine whether this
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segregation of PTEN and SHIP function between “seed” and “soil” is also
conserved in other stem cell populations and their supporting milieu. Functional
segregation of these signaling components suggests that selective targeting of
these two phosphoinositide signaling enzymes might be of value in clinical
settings where specific modulation of HSC or niche function is warranted.

Methods
Mice
Production of SHIP-/- and MxCreSHIPflox/flox mice has been previously
described11,86. Briefly, SHIP-/- mice were generated by deletion of the promoter
and first exon of SHIP via a Cre-LoxP strategy and backcrossed to a C57BL6/J
background. MxCreSHIPflox/flox mice were generated using SHIPflox/flox and MxCre
mice (Jackson Laboratory, Bar Harbor, ME). MxCreSHIPflox/flox:WT-Ly5.1 and
SHIPflox/flox:WT-Ly5.1 BM chimeras were created by co-transplanting 5X105 WBM
cells from MxCreSHIPflox/flox(CD45.2+) or SHIPflox/flox(CD45.2+) plus 5X105 cells
from WT-Ly5.1(CD45.1+) mice into lethally irradiated CD45.1+45.2+ recipients. All
animal experiments were conducted with approval of the Univ. of South Florida
IACUC.

Cell Isolation
Bone marrow (BM) cells were flushed from femurs and tibias, red blood cell
(RBC) lysed, centrifuged and resuspended in staining media (SM) composed of
Dulbecco phosphate-buffered saline (D-PBS), 3%FBS, and 10mM HEPES. For
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transplantation, WBM was simply flushed, washed and resuspended in sterile
PBS. Spleens were manually crushed then treated like BM cells. Peripheral
blood (PB) was collected in microtainers with K2EDTA (BD, Franklin Lakes, NJ).
RBC lysis was performed twice to obtain PB mononuclear cells (PBMC).

Conditional Deletion of SHIP
MxCreSHIPflox/flox(CD45.2+) mice and MxCreSHIPflox/flox:WT-Ly5.1 BM chimeras
were conditionally ablated for SHIP expression through intra-peritoneal injection
of polyinosinic-polycytidylic acid (polyI:C) (Sigma-Aldrich, St. Louis, MO). Mice
were injected three times with 625μg of polyI:C on days 1, 4, and 7.

Flow Cytometry
All antibodies were from BD Biosciences (San Jose, CA), eBioscience (San
Diego, CA) or CalTag/Invitrogen (Carlsbad, CA). PBMC, splenocytes or BM cells
were treated with CD16/CD32 mouse Fc block(2.4G2) on ice for 20 minutes then
stained with a panel of antibodies. Global reconstitution was assessed by
staining with: CD45.1-PE(A20) and CD45.2-FITC(104) or CD45.1-PE(A20) and
CD45.2-PercpCy5.5(104). Multi-lineage reconstitution was assessed by staining
with: CD45.1-PE(A20), CD45.2-PercpCy5.5(104), B220-AlexaFluor700(RA36B2), CD3-PECy7(145-2C11), Mac1-APCCy7(M1/70) and NK1.1-APC(PK136).
Myeloid, erythroid and megakaryocytic reconstitution was assessed by staining
with: CD45.1-PE(A20), CD45.2-PercpCy5.5(104), Mac1-APCCy7(M1/70), Gr1FITC(RB6-8C5), or CD41-FITC(MWReg30) and Ter119-APC(TER-119).
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Phenotypic HSC were assessed by staining with: CD45.1-Purified(A20)
conjugated to Pac Orange using Zenon technology, CD45.2-PerCPCy5.5(104),
Sca1-PECy7(D7), c-Kit-APC-AF750(2B8), CD48-APC(HM48-1), CXCR4PE(2B11/CXCR4), and a lineage (Lin) panel on FITC; CD2(RM2-5), CD3(1452C11), CD4(GK1.5), CD5(53-7.3), CD8(53-6.7), B220(RA3-6B2), Gr-1(RB68C5), Mac-1(M1/70), NK1.1(PK136) and Ter119(TER-119) or Sca1-FITC(E13161.7), c-Kit-PECy7(2B8), CD48-APC(HM48-1), CXCR4-biotin(2B11/CXCR4),
and a Lin panel on PE; CD2(RM2-5), CD3(145-2C11), CD4(GK1.5), CD5(537.3), CD8(53-6.7), B220(RA3-6B2), Gr-1(RB6-8C5), Mac-1(M1/70),
NK1.1(PK136), and Ter119(TER-119) followed by a secondary stain of
Steptavidin-AF700. Microenvironment cells were assessed in BM by: CD2FITC(RM2-5), CD3e-FITC(145-2C11), CD4-FITC(GK1.5), CD5-FITC(53-7.3),
CD8a-FITC(53-6.7), CD41-FITC(MWReg30), B220-FITC(RA3-6B2), Ter119FITC(TER-119), NK1.1-FITC(PK136), Mac1-FITC(M1/70), GR1-FITC(RB6-8C5),
and VCAM1-AF647(429). After 20 minutes of staining on ice the cells were
washed and resuspended in SM containing 75ng/ml of 4',6-diamidino-2phenylindole dihydrochloride (DAPI) (Sigma, Saint Louis, MO) for dead cell
exclusion. All flow cytometry acquisition was done on a FACS LSRII (BD
Biosciences), a FACS ARIA (BD), or a FACS Vantage (BD). Data was analyzed
using FlowJo® software (Tree Star, Inc. Ashland, OR).
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In Situ SHIP Deletion BM Transplants
5x105 MxCreSHIPflox/flox(CD45.2+) or SHIPflox/flox(CD45.2+) WBM cells were cotransplanted (i.v.) with 5x105 WBM competitor cells from WT-Ly5.1(CD45.1+)
mice into lethally irradiated CD45.1+45.2+ recipients. Recipients received a split
dose of 11-Gy at least 2-hours before transplantation. After 60 days recipient
mice were treated with the polyI:C series.

Secondary BM Transplants from In Situ SHIP Deleted Mice
Five months after polyI:C treatment of MxCreSHIPflox/flox:WT-Ly5.1 and
SHIPflox/flox:WT-Ly5.1 BM chimeras, mice were sacrificed and 1x106 WBM cells
were transplanted (i.v.) into lethally irradiated CD45.1+45.2+ recipients.

Systemic SHIP Deletion BM Transplants
MxCreSHIPflox/flox(CD45.2+) mice and SHIPflox/flox(CD45.2+) mice were pre-treated
with the polyI:C series. SHIP deletion was confirmed by Western blot of PBMC.
5x105 WBM cells from MxCreSHIPflox/flox(CD45.2+) or SHIPflox/flox(CD45.2+) mice
were co-transplanted (i.v.) with 5x105 WBM competitors from WT-Ly5.1(CD45.1+)
mice into lethally irradiated CD45.1+45.2+ recipients.

Western Blot Detection of SHIP and -actin Expression
Cell lysates were prepared from cultured or sorted cells using modified RIPA
lysis buffer (Upstate Cell Signaling, Millipore, Billerica, MA). Lysate supernatants
were resolved on a 4-12% Bis-Tris gel, and transferred to a Hybond-ECL
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nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ). For Odyssey
technology, the membrane was blocked with Odyssey blocking buffer (LICOR
Biosciences, Lincoln, NE) and probed with 1-5μg/ml P1C1 (Santa Cruz
Biotechnology, Santa Cruz, CA) then anti-mouse IR-700 at 1:8,000 (Molecular
Probes, Carlsbad, CA). Probed blots were scanned using an Odyssey infrared
imager. For chemi-luminescence, the membrane was blocked with 5% non-fat
milk in PBS with 0.1% Tween-20 (PBS-T) and probed with 1μg/ml P1C1 or
1μg/ml Actin:C-11 (Santa Cruz Biotechnology) followed by anti-mouse IgG-HRP
or anti-goat IgG-HRP at 1:1,000 (eBioscience). Protein was detected using
SuperSignal West Femto Substrate (Thermo Scientific, Rockford, IL).

Calculation of Repopulation Units
Repopulating units (RU) were calculated as per Harrison et al.167: (C*CD45.2
repopulation(%))/(100-CD45.2 repopulation(%)), where 1C= 105 competitor cells.
Since we used 5x105 competitor cells, we used this equation:
RU = (5 * CD45.2 repopulation(%))/(100 – CD45.2 repopulation(%)).

ELISA Detection of Cytokines
Serum was isolated from PB and stored at -20ºC or sent for analysis by a service
from Charles Rivers Laboratories Inc., where ELISA for multiple cytokines was
performed. BM plasma was assayed for cytokines by flushing cleaned femurs
with 500μl PBS. The PBS was then centrifuged at 1800 rpm for 5 minutes at 4ºC.
The supernatant was removed to a new tube and stored at -20ºC. Cell culture
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supernatants were harvested at regular intervals and stored at -20ºC. Stored
supernatants were then assayed for stromal cell derived factor-1 (SDF-1) using
the Quantikine® Immunoassay (R&D Systems, Minneapolis, MN).

Isolation and Culture of Stromal Cells
Bone marrow was flushed from intact femurs and tibias into tissue culture flasks
containing alpha-modified MEM with nucleotides (-MEM)168. The -MEM was
supplemented with 15% FBS, 50 units penicillin-G/mL, 50μg streptomycin/mL,
0.3μg amphotericin-B/mL, and 50μg ascorbate/mL. After culturing cells for three
days undisturbed, media was changed and non-adherent cells removed.

Isolation and Culture of Osteoblasts
Cleaned and flushed femurs and tibias were scraped using a scalpel to remove
remaining soft tissue169. The bones were cut into 1-2mm2 pieces and incubated
with shaking in a solution of 2 mg collagenase-II/mL in modified DMEM at 37°C
for 2 hours. Complete culture medium (cCM) was added to stop the collagenase
action. The cCM consisted of DMEM (pH 7.4) supplemented with 2.2g
NaHCO3/L, 10% FBS, 50 units penicillin-G/mL, 50μg streptomycin/mL, 50 μg
gentamycin/mL, 1.25μg amphotericin-B/mL, and 100μg ascorbate/mL. The bone
pieces were washed three times with cCM and cultured in 25cm2 tissue culture
flasks.
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SHIP Immunoprecipitation and Western Blot for Phosphotyrosine
Stromal cell cultures were lysed in modified RIPA buffer. SHIP was
immunoprecipitated overnight with 0.2μg P1C1 and protein A/G-agarose beads
from precleared lysate supernatants. The immunoprecipitated protein was blotted
and the membrane blocked using the protocol above. It was then probed using
an anti-phosphotyrosine, HRP-conjugated monoclonal antibody (4G10, Santa
Cruz Biotechnology) diluted 1:1000 with 3% milk in PBS-T. Phosphorylated
tyrosine was detected using SuperSignal West Femto Substrate diluted 1:5 with
Pierce ECL Western Blotting Substrate (Thermo Scientific).

ELF97 Alkaline Phosphatase Assay
Alkaline phosphatase (ALP) activity was measured using an ELF97 assay
(Invitrogen) modified for flow cytometry160. Osteoblasts were fixed overnight in
70% EtOH at 4°C. Cells were then washed and transferred into FACS tubes.
After pre-incubation with developing buffer, phosphate substrate was added to
the cells. The cells were incubated at room temperature for 1-30 minutes before
adding a phosphatase inhibitor, levamisole (10mM), to stop the reaction.

Co-culture Proliferation Assay
Hematopoietic progenitor cells160 (HPC) were isolated from WT mice by lineage
depletion of BM using an antibody cocktail on PE: CD3(145-2C11),
CD4(GK1.5), CD5(53-7.3), B220(RA3-6B2), Gr-1(RB6-8C5), Mac-1(M1/70), and
Ter119(TER-119) followed by a magnetic enrichment using anti-PE microbeads
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(Mitenyi Biotec, Auburn, CA). HPC were loaded with 5μM carboxyfluorescein
succinimidyl ester (CFSE). WT CFSE+ HPC were co-cultured with confluent
SHIP-/- or WT stromal cells for 36hrs. Proliferation was assayed based on loss of
CFSE in Lin-cKit+Flk2- cells by staining with: a Lineage-PE panel (CD3, CD4,
CD5, B220, Ter119, Mac1, Gr1), cKit-APC (Miltenyi Biotec), Flk2-PE(A2F10.1)
and DAPI.

Histology
Femurs were embedded in O.C.T. compound (Tissue-Tek, Torrance, CA), snapfrozen in liquid nitrogen and stored at -80°C. Cryostat sections (10μm) were
fixed, pre-incubated in blocking buffer (PBS, 3% BSA, anti-CD32/CD16(2.4G2)),
and stained with antibodies. Sections were embedded in Fluorescent Mounting
Medium (Dako Cytomation, Denmark) and analyzed by confocal microscopy
(Leica TCS-SL, Leica, Bannockburn, IL) using a 63x objective. Image processing
was performed with the Leica Confocal Software. Cryostat sectioning, staining
and microscopy were jointly performed by Oliver Winter and Katrin Moser from
the German Rheumatism Research Center in Berlin Germany.

Statistical Analysis
All statistical analyses were performed using Prism® (GraphPad, San Diego,
CA).
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Functional HSC in the Periphery of SHIP-Deficient Mice

Abstract
Previously we showed that SHIP-deficiency compromises the function of
HSC and their supporting cells in the BM. This leads to splenomegaly and
increased numbers of splenocytes possessing an HSC phenotype suggesting the
spleen of SHIP-/- mice could be a source of definitive hematopoiesis. Consistent
with this hypothesis, we show that SHIP-/- splenocytes possess all major
functions of bona fide HSC, including radioprotection, long-term multi-lineage
repopulation and self-renewal. Moreover, we find that purified splenic SHIP-/HSC have equivalent stem cell capacity to that of SHIP-competent BM HSC.
Analysis of Akt activation and inhibition of PI3K signaling in vivo indicates
dysregulated PI3K/Akt signaling enables SHIP-/- HSC to function normally outside
the confines of their niche in BM. These findings suggest that targeting of SHIP
could be used to safely evacuate a functional HSC compartment to the spleen in
the event of damage to the BM niche.

Introduction
Phosphoinositide 3-kinase (PI3K) signaling plays a crucial role in the fate
of a cell170. When this signaling pathway is disrupted by loss of an inositol
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phoshatase, key steps such as the hydrolysis of PI(3,4,5)P3 are lost and control
of downstream signaling becomes aberrant43,170,171. The SH2-domain containing
inositol phosphatase (SHIP) is an enzyme that removes the 5’ phosphate from
PI(3,4,5)P3 and generates PI(3,4)P21-3,5,60. This activity regulates PI(3,4,5)P3
levels in the cell and thus contributes to the controls of survival signaling by
limiting the downstream activation of PKB/Akt. Consistent with this we have
previously shown that SHIP promotes turnover of peripheral NK cells in vivo by
limiting Akt activation and expression11.
SHIP is primarily expressed in the hematopoietic system1,3,5, although its
expression has also been documented in osteoblasts, bone marrow (BM) stromal
cells, embryonic fibroblasts and endothelial cells139,142,172. Several perturbations
of mature hematopoietic cells as well as hematopoietic stem cells (HSC), have
been documented in SHIP-deficient mice. It has a significant role in NK
cells11,145,173, B lymphocytes147,174, myeloid cells148, macrophages82,
osteoclasts83, dendritic cells85 and immunoregulatory cells85,86,175,176.
Furthermore, we previously showed a crucial role for SHIP in the regulation of
the BM HSC compartment136,172. Initial transplant studies showed that SHIP-/- BM
HSC were compromised in their ability to provide long term multi-lineage blood
repopulation in competition with wild type (WT) BM HSC suggesting an intrinsic
role for SHIP in HSC function136. However, our recent studies have also revealed
a crucial role for SHIP in the function of niche cells that support HSC in the
BM172. Taken together these studies reveal a complex role for SHIP in the control
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of HSC function with both cell autonomous and extrinsic in vivo effects being
possible.
In an in situ SHIP deletion model, in which BM resident HSC are rendered
SHIP-deficient while they are resident in a SHIP-competent milieu, we observed
significant HSC peripheralization to the spleen and splenomegaly suggesting a
cell autonomous role for SHIP in limiting HSC function to the BM. Although not
the primary supply during adulthood, the spleen can be a significant source of
HSC and definitive hematopoiesis early in ontogeny177. Here we show that lack
of SHIP causes relocation of a functional HSC compartment to the spleen.
Furthermore, we show that increased PI3K/Akt signaling in SHIP-/- HSC
preferentially sustains this peripheralized HSC compartment.

Results
SHIP-/- Splenocytes Exhibit All Major Features of Bona Fide HSC
We recently found that MxCreSHIPflox/flox:WT BM chimeras develop
splenomegaly after induction of SHIP-deficiency (Figure 26), suggesting there
might be significant HSC activity and definitive hematopoiesis in the spleen when
SHIP-deficient HSC are present in an animal.
To determine if there was significant HSC activity in the spleens of SHIP-/mice we transplanted lethally irradiated Ly5 congenic hosts with 0.5x106
splenocytes from SHIP-/- or WT donors. Consistent with the presence of
significant HSC numbers, SHIP-/- splenocytes protected >90% of lethally
irradiated recipients while only <30% that received WT splenocyte grafts survived
72

for at least 30 days (Figure 27A). Analysis of blood cell repopulation in BM,
spleen and blood at 4 months post-transplant showed that global donor
hematopoietic repopulation was ~50% for mice transplanted with SHIP-/splenocytes (Figure 27B and data not shown). SHIP-/- splenocytes also
contributed significantly to repopulation of multiple lineages including the B
lymphoid, T lymphoid and myeloid/granulocytic lineages (Figure 27B). Thus, the
splenic HSC compartment in SHIP-deficient donors is capable of radioprotection
and extended multi-lineage repopulation. The mice reconstituted with SHIP-/splenocytes also exhibited splenomegaly at 4 months post-transplant (Figure 28),
indicating peripheralized HSC retain the bias toward extramedullary
hematopoiesis even after transplant into SHIP-competent mice.
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Figure 26: SHIP-deficient HSC are peripherally biased.
Splenomegaly in MxCreSHIPflox/flox/Ly5.1-BL6 BM chimeras post-deletion.
MxCreSHIPflox/flox:WT (-/-:WT) and SHIPflox/flox:WT (+/+:WT) BM chimeras were
established in Ly5.1+5.2+ hosts and then SHIP was deleted by three injections of
polyI/C. Five months later the spleens were removed and photographed. Three
representative spleens from each type of chimera are shown.

Figure 27: SHIP-deficient splenocytes have significant repopulating
activity.
(A) A representative survival curve of lethally irradiated Ly5.1+5.2+ hosts that
received a splenocyte graft (0.5x106 cells/mouse) from either a SHIP-/- donor
(n=24) or a WT donor (n=26). (B) Global hematopoietic and lineage-specific
donor repopulation at 4 months post-transplant for SHIP-/- splenocyte
transplanted mice based on Ly5.2+5.1- staining of total PBMC (Global),
Ly5.2+5.1- staining of B220+ B lymphoid cells (B220), of CD3+ T lymphoid cells
(CD3) of Mac1+ or Gr1+ myeloid cells (MacGr). Survival differences were
assessed by the Kaplan-Meier log-rank test. The significance of differences in
repopulation were assessed by a Student’s T-test and unless indicated are not
significant. [***p<0.001] [SHIP-/- graft, RED; WT graft, BLACK]
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Figure 28: SHIP-deficient splenocytes provide hematopoiesis but remain
peripherally biased.
Splenomegaly at four months post-transplant in recipients reconstituted with
SHIP-/- splenocytes (Null) as compared to mice reconstituted with WT
splenocytes (WT). Three representative spleens from each transplant group are
shown.
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The unique feature of the HSC is its ability to self-renew as measured by
its ability to repopulate multiple-lineages upon serial transplantation. As an initial
indication of self-renewal by HSC present in the SHIP-/- splenocyte graft we
observed greater donor reconstitution of the cKit+Lin-Scai+CD48- (KLSCD48)178
HSC compartment in the spleens of primary recipients reconstituted with SHIP-/splenocytes as compared to primary recipients reconstituted with WT
splenocytes (Figure 29). This finding is consistent with the splenomegaly and
extramedullary hematopoiesis observed in Figure 28.
To further assess self-renewal, we then serially transplanted secondary
recipients with 0.5X106 splenocytes from the primary recipients. As with the
primary transplants, the serial transfer of splenocytes from primary recipients that
received SHIP-/- splenocytes were significantly more radioprotective than
splenocytes from primary recipients that received WT splenocytes (Figure 30A).
Analysis of peripheral blood at 4 months post-transplant in these secondary
recipients confirmed that the mice had significant multi-lineage and global
hematopoietic repopulation derived from the original primary SHIP-/- splenocyte
graft (Figure 30B). These findings demonstrate the existence of a robust
extramedullary HSC compartment in SHIP-/- mice that is capable of
radioprotection, long-term multi-lineage repopulation and self-renewal.
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Figure 29: SHIP-deficient splenocytes have significant HSC activity.
Donor HSC repopulation at 4 months post-transplant for mice based on a
Ly5.2+5.1- gate on the KLSCD48 HSC present in viable splenocytes. Mice
originally received either a SHIP-/- (Null) splenoctye graft or a wild type (WT)
splecnocyte graft. The significance of differences in repopulation were assessed
by a Student’s T-test. [*p<0.05] [SHIP-/- graft, RED; WT graft, BLACK]

Figure 30: SHIP-deficient splenocytes have significant HSC self-renewal.
(A) A representative survival curve of lethally irradiated Ly5.1+5.2+ secondary
hosts that received a splenocyte graft (0.5x106 cells/mouse) from primary donors
reconstituted with SHIP-/- (Null) splenocytes (n=19) or WT (WT) splenocytes
(n=13). (B) Global hematopoietic and lineage specific donor repopulation at 4
months post-transplant for secondary mice that received a splenocyte graft from
a primary host, which originally received a SHIP-/- graft. Survival differences
were assessed by the Kaplan-Meier log-rank test. [**p<0.005] [SHIP-/- graft, RED;
WT graft, BLACK]
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SHIP-/- Splenic HSC are Equally Potent to Bona Fide SHIP-competent BM
HSC
The above studies established the presence of a robust HSC
compartment in the spleens of SHIP-deficient mice. Our previous study found
increased mobilization, poor homing and compromised function by BM HSC in
SHIP-/- mice136, suggesting that a significant portion of the HSC compartment
might be relocated to the spleen of these mice. To examine this question we
directly compared the function of splenic SHIP-/- HSC to that of BM HSC from
normal mice. To accomplish this we sorted equal numbers of KLSCD48 HSC
from spleens of SHIP-/- and WT mice as well as KLSCD48 HSC from the BM of
WT mice (Figure 31). Equal numbers of these three HSC populations were
transplanted into lethally irradiated mice without the aid of supporting BM cells to
directly compare their capacity to radioprotect lethally irradiated hosts. SHIP-/splenic HSC protected >80% of lethally irradiated hosts, which in fact provides a
comparable level of radioprotection as that provided by bona fide WT BM HSC
(Figure 32). However, we find that KLSCD48 HSC sorted from the spleens of WT
mice are incapable of significant radioprotection (Figure 32). These findings
indicate a functional BM HSC compartment is not only relocated to the spleen in
SHIP-deficient mice, but is qualitatively comparable to WT BM HSC.
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Figure 31: Purification of HSC from SHIP-/- spleen, WT BM and WT spleen.
Representative FACS plots demonstrating the isolation of KLSCD48 HSC for
transplantation from SHIP-/- spleen (LEFT), WT BM (CENTER) or WT spleen
(RIGHT).

Figure 32: SHIP-/- splenic HSC have radioprotective capacity equivalent to
WT BM HSC.
A representative survival curve of lethally irradiated Ly5.1+5.2+ hosts that
received a KLSCD48 HSC graft (200 cells/mouse) purified from either SHIP-/spleen (n=19), WT spleen (n=17) or WT BM (n=20) as indicated. Survival
differences were assessed by the Kaplan-Meier log-rank test. [**p<0.005] [SHIP-/spleen graft, RED; WT BM graft, BLACK; WT spleen graft, GRAY]
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Analysis of peripheral blood at 4 months post-transplant in the surviving
recipients confirmed that the mice had significant multi-lineage and global
hematopoietic repopulation derived from the original primary SHIP-/- splenic
KLSCD48 HSC or WT BM KLSCD48 HSC graft (Figure 33 and data not shown).
These findings demonstrate the existence of a robust extramedullary HSC
compartment in SHIP-/- mice that is qualitatively comparable to a bona fide BM
HSC.

Figure 33: SHIP-/- splenic HSC have reconstituting capacity equivalent to
WT BM HSC.
Lineage-specific donor repopulation at 4 months post-transplant form surviving
SHIP-/- spleen KLSCD48 HSC and WT BM KLSCD48 HSC transplanted mice
based on staining of PBMC for Ly5.2+5.1- and staining of B220+ B lymphoid cells
(B220), of CD3+ T lymphoid cells (CD3) and of Mac1+ or Gr1+ myeloid cells
(MacGr). The significance of differences in repopulation were assessed by a
Student’s T-test and unless indicated are not significant. [SHIP-/- spleen graft,
RED; WT BM graft, BLACK]
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Induction of SHIP-deficiency in Normal Adult Physiology Evacuates HSC to
the Spleen
The above experiments did not address whether SHIP-deficiency causes
a developmental defect that enables fetal and neonatal HSC to continue to reside
in the spleen rather than completing their migration to the BM during ontogeny. If
this were the case, then induction of SHIP-deficiency in adult mice would not
result in relocation of HSC to the spleen. To test this possibility, we induced
SHIP-deficiency in MxCreSHIPflox/flox mice by injection of polyinosinic-polycytidylic
acid (polyI/C) and then quantitated HSC in the spleen and blood 21 days later
using the KLSCD48 HSC phenotype. Similar to our observations in
MxCreSHIPflox/flox:WT BM chimeras (Figure 26), MxCreSHIPflox/flox mice develop
splenomegaly after induction of SHIP-deficiency (Figure 34), again suggesting
hematopoiesis in the spleen.
As we observed with germline SHIP-deficient mice136, HSC numbers are
significantly increased in both the blood and spleen of MxCreSHIPflox/flox mice
relative to their SHIPflox/flox controls treated with an identical polyI/C regimen
(Figure 35A-B). These findings demonstrate that during adult physiology SHIP is
required for BM retention of HSC.
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Figure 34: Induced SHIP deficiency in the adult causes extramedullary
hematopoiesis.
Splenomegaly in MxCreSHIPflox/flox but not SHIPflox/flox controls after polyI/C
treatment. Two representative spleens from MxCreSHIPflox/flox (CRE+) or
SHIPflox/flox (CRE-) controls are shown.

Figure 35: Induced SHIP deficiency in the adult mobilizes HSC to the blood
and spleen.
(A) Representative flow cytometric quantitation of KLSCD48 HSC in PB of
MxCreSHIPflox/flox and SHIPflox/flox controls after polyI/C stimulated deletion of
SHIP. Mice received three polyI/C injections on days 1, 4 and 7 and then HSC
were quantitated in the indicated tissues 21 days later by flow cytometry. (B) A
similar flow cytometric quantitation of KLSCD48 HSC in Spleen of
MxCreSHIPflox/flox and SHIPflox/flox controls after polyI/C. The significance of
differences were assessed by a Student’s T-test. [*p<0.05, **p<0.005]
[MxCreSHIPflox/flox, RED; SHIPflox/flox, BLACK]
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Aberrant PI3K/Akt Signaling Sustains the Peripheralized HSC Compartment
in SHIP-/- Mice
Like its s-SHIP isoform expressed in pluripotent stem cells41,139, SHIP can
be recruited to key growth factor receptor complexes to oppose PI3K and thus
limit HSC proliferation and/or survival. We proposed then that SHIP-deficient
HSC may have higher levels of PI3K/Akt signaling that enables their survival
outside the BM milieu where suboptimal concentrations of key HSC growth and
survival factors are present. Consistent with this hypothesis, we observe elevated
levels of Akt phosphorylation in SHIP-deficient hematopoietic stem/progenitor
cells (HS/PC) (Figure 36).

Figure 36: SHIP-deficiency results in aberrant PI3K/Akt signaling in HSC.
Representative median fluorescence intensity (MFI) values for phosphorylated
AKT levels in KLS cells from SHIP-/- spleens or WT BM as assessed by flow
cytometry. The significance of differences were assessed by a Student’s T-test.
[***p<0.005] [SHIP-/-, RED; WT, BLACK]
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In addition, inhibition of PI3K signaling in vivo by treatment with a potent
PI3K inhibitor, Wortmannin, leads to a significant reduction in spleen size, total
splenocytes and splenic HSC numbers in wortmannin-treated SHIP-/- mice as
compared to the vehicle-treated group (Figure 38A-B). Taken together, these
findings demonstrate that aberrant PI3K/Akt signaling sustains the splenic SHIP-/HSC compartment and their hematopoietic output.

Figure 37: Aberrant PI3K/Akt signaling contributes to splenomegaly in
SHIP-/- mice.
Images of spleens showing reduced splenomegaly in SHIP-/- mice treated with
0.7mg/kg Wortmannin (Inhibitor) compared to Vehicle (Vehicle) for 7 days.

84

Figure 38: Aberrant PI3K/Akt signaling contributes to peripheral existence
of SHIP-/- HSC.
(A) Quantitative comparison of viable cell counts from spleens of Wortmannin
(Inhibitor) or Vehicle (Vehicle) treated SHIP-/- and WT mice. (B) Flow cytometric
quantitation of KLSCD48 HSC in spleen of SHIP-/- and WT mice treated for 7
days with 0.7mg/kg Wortmannin (Inhibitor) or Vehicle (Vehicle) alone. The
significance of differences were assessed by a Student’s T-test and unless
indicated are not significant. [*p<0.05, **p<0.01] [SHIP-/-, RED; WT, BLACK]
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Discussion
The variety of phenotypes associated with SHIP-deficiency indicate SHIP
has diverse roles in mammalian biology11,82,83,85,86,136,145,147-149,173-175. A complete
understanding of the role that SHIP plays in HSC biology at both the molecular
and cellular level has yet to be fully defined. We recently showed that SHIP plays
a crucial role in the function of BM niche cells that support HSC activity172.
Deregulated production of G-CSF, compromised SDF-1 production and
suppression of CXCR4 expression by the altered BM niche may all contribute to
the peripheralization of HSC to the spleen in SHIP-/- mice136,172. However, the
findings shown here indicate an additional cell autonomous role for SHIP in HSC
function. We find that SHIP-deficient HSC are capable of a sustained existence
in the spleen of SHIP-competent hosts and, moreover, that deregulated PI3K/Akt
signaling contributes to this sustained peripheral existence.
Recently work has been done to indicate there might be an extramedullary
HSC niche in the spleen consisting of megakaryocyte like cells (MLC)179. These
MLC express several factors important to the osteoblastic niche in BM, such as
N-Cadherin and SDF-1. Interestingly, our group has shown that SHIP-/- spleens
contain increased numbers of megakaryocytes180, indicating a potential
extramedullary HSC niche. Here we show that these SHIP-/- extramedullary HSC
are capable of providing comparable radioprotection to WT BM derived HSC in
addition to long term multi-lineage repopulation when transplanted into lethally
irradiated hosts. To our knowledge this is the first work to suggest a role for SHIP
in the survival of HSC in the periphery.
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In spite of the negative repercussions for loss of SHIP, a short-term
inhibition of SHIP could prove beneficial in a setting of BM failure. It is tempting to
speculate on the implications these findings may have for clinical application.
We propose that reversible inhibition of SHIP could be utilized when medullary
hematopoiesis is selectively compromised by exposure to infectious agents,
radioisotopes or chemicals that selectively target BM. Our findings here
demonstrate that induced SHIP-deficiency could evacuate a sufficient number of
HSC to the spleen that are equally potent to BM HSC. This “refugee” HSC
compartment could support definitive hematopoiesis until such time as the BM
microenvironment recovers from acute stress allowing return of HSC to their
normal niche. Previously we advocated the use of SHIP inhibition strategies to
abrogate host-versus-graft and graft-versus-host immune responses in
allogeneic BM transplantation11. Our findings here indicate that such an approach
could be applicable to recovery and maintenance of autologous blood cell
production in a variety of therapeutic settings.

Methods
Mice
The development and production of SHIP-/- and MxCreSHIPflox/flox mice has
previously been described by our group11,86. MxCreSHIPflox/flox:WT and
SHIPflox/flox:WT BM chimeras were created by co-transplanting 0.5X106 WBM
cells from MxCreSHIPflox/flox or SHIPflox/flox (Ly5.2+) with 0.5X106 WBM cells from
WT (Ly5.1+) mice into lethally irradiated Ly5.1+Ly5.2+ recipients172. Two months
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later both cohorts received three injection of polyI/C as described below. The
spleens pictured in Figure 26 were removed at least 4 months after deletion of
SHIP from representative members of the MxCreSHIPflox/flox:WT (-/-:WT) and
SHIPflox/flox:WT (+/+:WT) cohorts.

Splenocyte Transplants
0.5x106 germline SHIP-deficient (Ly5.2+) splenocytes or 0.5x106 WT (Ly5.2+)
splenocytes were transplanted by retro-orbital (r.o.) injection into separate groups
of lethally irradiated WT (Ly5.1+Ly5.2+) recipients. In all transplants, recipient
mice were given antibiotic water prior to receiving a split dose of 11-Gy at least 2hours before transplantation.

Secondary Splenocyte Transplants
At least 4 months after the primary splenocyte transplant, animals were sacrificed
and 0.5x106 spleen cells were transplanted (r.o.) into lethally irradiated WT
(Ly5.1+Ly5.2+) recipients.

HSC Transplants
KLSCD48 HSC were isolated by fluorescence-activated cell sorting (FACS) from
WT BM, SHIP-/- spleen or WT spleen. Then 200 purified KLSCD48 cells from
each group were transplanted (r.o.) into separate lethally irradiated WT
(Ly5.1+Ly5.2+) recipients.
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Conditional Deletion of SHIP
MxCreSHIPflox/flox mice were conditionally deleted for SHIP through the intraperitoneal (i.p.) injection of polyinosinic-polycytidylic acid (polyI/C) (SigmaAldrich, St. Louis, MO). Mice were injected three times with 625g of poly(I:C) on
days 1, 4, and 7.

Assessment of Donor Reconstitution in PBMC
All antibodies were from BD Biosciences (San Jose, CA), eBioscience (San
Diego, CA) or Invitrogen (Carlsbad, CA) unless otherwise noted. Peripheral blood
was collected and red blood cell lysis performed as previously described136.
Peripheral blood mononuclear cells (PBMC) were treated with CD16/CD32
mouse Fc block (2.4G2) on ice for 20 minutes then stained with a panel
containing: CD45.1-PE (A20), CD45.2-FITC, B220-AlexaFluor700 (RA3-6B2),
CD3-PECy7 (145-2C11), Mac1-APC (M1/70) and Gr1-APC (RB6-8C5). After a
20-minute incubation on ice the cells were washed and resuspended in media
containing 75ng/ml of 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) for
dead cell exclusion (Sigma, Saint Louis, MO). Acquisition was done on a FACS
LSRII (BD Biosciences) and data analyzed using FlowJo® software (Tree Star,
Inc. Ashland, OR).

KLSCD48 HSC Sorting
C-kit+ splenocytes or BM were enriched using an AutoMACS magnetic
enrichment system with anti-cKit (Miltenyi Biotec, Auburn, CA) magnetic beads.
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The positive fraction was then stained for the Lineage-/lowc-Kit+Sca1+CD48(KLSCD48) phenotype129 for 20 minutes on ice using the following antibody
panel: cKit-APC (Miltenyi Biotec), Lineage panel-FITC, CD48-PE (HM48-1),
Sca1-PECy7 (D7). The lineage panel consisted of: CD2 (RM2-5), CD3e (1452C11), CD4 (GK1.5), CD5 (53-7.3), CD8a (53-6.7), B220 (RA3-6B2), Gr-1 (RB68C5), Mac-1 (M1/70), NK1.1 (PK136), CD41 and Ter119 (TER-119). After
staining, the cells were washed and resuspended in staining medium containing
75ng/ml of DAPI for dead cell exclusion. Sorting was performed on a FACS Aria
(BD Biosciences).

KLSCD48 HSC Analysis
Peripheral blood and splenocytes were harvested and red blood cell lysis was
performed. PBMC and splenocytes were treated with CD16/CD32 mouse Fc
block on ice for 20 minutes then stained with a panel for the KLSCD48phenotype containing: cKit-APC, Lineage panel-FITC, CD48-PE, Sca1-PECy7.
The lineage panel was identical to the previously described panel. After staining,
the cells were washed and resuspended in medium containing 75ng/ml of DAPI
for dead cell exclusion. Acquisition was done on a FACS LSRII and data
analyzed using FlowJo® software.

Intracellular Flow Cytometry
Tissues were harvested on ice in PBS with 5% serum. A single cell suspension
was prepared, then cells were centrifuged (5 min, 300g) to pellet and resuspend
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in 20 volumes of pre-warmed (37°C) Lyse/Fix buffer (BD Phosflow Lyse/Fix, BD
Biosciences). Cells were incubated at 37°C for 10 mins. After fixation, cells were
pelleted again and permeabilized by adding 1ml Perm/Wash buffer (BD
Phosflow, Perm/Wash I, BD Biosciences) per 10 million cells. Cells were
incubated at room temperature for 10 mins then washed twice in 5 ml
Perm/Wash buffer. Cells were resuspend in BD Stain buffer (BD Stain Buffer, BD
Biosciences) at 100ul/million and treated with CD16/CD32 mouse Fc block on ice
for 20 minutes. Then cells were stained with a panel for both intracellular and
extracellular antibodies at room temperature for 30 mins. The panel for the KLS
phenotype consisted of: Lineage panel-FITC, cKit-PECy7 (2B8), Sca1-APC (D7).
The lineage panel was identical to the previously described panel. In addition, the
antibody pAKT(T308)-PE (BD Biosciences) was used to assess levels of
activated Akt. After staining the cells were washed once in BD Stain buffer and
resuspend for flow cytometric analysis. Acquisition was done on a FACS LSRII
and data analyzed using FlowJo® software.

PI3K Inhibitor Studies
Cohorts of SHIP-/- or WT mice were weighed and treated daily, for 7 consecutive
days, with 0.7mg/kg Wortmannin (Sigma-Aldrich, St Louis, MO) dissolved in a
Tween-20 vehicle and diluted in 500ul sterile PBS per i.p. injection per mouse,
for ease of injection. Separate cohorts of SHIP-/- or WT mice were weighed and
treated daily with Tween-20 vehicle alone, which was also dissolved in 500ul
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sterile PBS per i.p. injection per mouse. On day 8 all mice were sacrificed for
further analysis.

Statistical Analysis
All statistical analyses were performed using Prism® (GraphPad, San Diego,
CA).
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Defining the Hematopoietic Kinome

Abstract
Most cellular processes are regulated by the reversible phosphorylation of
proteins, rendering those proteins active or inactive. This phosphorylation occurs
on the amino acids serine (S), threonine (T) and tyrosine (Y) by protein kinases.
These kinases play a major role in regulating signaling cascades that determine
cell cycle entry, survival and the differentiation fate of cells in the mammalian
body, including the hematopoietic system. Therefore, an important goal is to
define those proteins that participate in phosphorylation-regulated signaling
pathways involved in hematopoietic development and differentiation. A massively
parallel and unbiased determination of the different kinase activities present in
hematopoietic cells would help elucidate fundamental molecular processes that
determine the unique biological properties of stem cells. We have collaborated
with a group that developed peptide array technology where 1,176 different
peptide substrates of kinases are arrayed in duplicate on a single chip. Our
collaborators have previously established that this technology can be applied to
whole cell lysates prepared from rare cell populations purified via high-speed cell
sorting. We have now begun to use this technology to conduct a parallel
assessment of the kinase signature or “kinome” of long-term repopulating
hematopoietic stem cells (LT-HSC), short-term repopulating HSC (ST-HSC),
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natural killer (NK) cells, B cells, T cells and myeloid cells. Our initial comparison
of the kinome profiles of LT-HSC and ST-HSC reveals a significant degree of
overlap in their respective kinomes, which is expected due to their close
proximity in the hematopoietic differentiation program. Similarly, fully
differentiated mature hematopoietic cells show many kinase similarities.
However, these comparisons do reveal several key differentially regulated
kinases. Here, we present kinome signatures that are specific to these discrete
subsets as well as the specific kinome signature of the HSC. A bioinformatic
approach was used to group differentially regulated kinases into common
functional categories allowing us to draw initial conclusions regarding the
biological relevance of these key differences. These kinome studies may provide
crucial information concerning the unique biological activities as hematopoietic
cells differentiate, including potential signaling pathways that control lineage
commitment.

Introduction
The transcriptome and proteome have been widely explored over the past
five years, mainly due to the development of array-based technologies181,182. In
particular, much analysis has been done to elucidate the genes important for
“stemness”. Several groups have done extensive array analyses and compiled
massive databases to determine what genes are important in giving stem cells
their unique properties183-186. Although many important genes came to light from
these analyses, there remain significant discrepancies between the two data94

sets185. Regardless of these initial ambiguities, this discovery driven type of
analysis can offer significant value to understanding the molecular mechanisms
that govern not only self-renewal but also the unique processes needed to
transition from HSC to fully differentiated immune cells. Until now, these array
based studies focused on identifying key genes involved in signaling. However,
equally important factors in regulation are the enzymes that are active in these
particular signaling pathways. Enzymes that phosphorylate tyrosine, serine and
threonine residues on proteins can determine survival and differentiation fates of
cells in the hematopoietic system. Because of the ambiguity of the current
stemness data, we applied a different approach to discover key signaling
interactions. Understanding the differences in active proteins will provide critical
information about cell biology. Toward this end, we have worked with a group
that developed a kinome analysis technique and we have applied this technology
to different subsets of hematopoietic cells including, LT-HSC, ST-HSC, B cells, T
cells, myeloid cells and NK cells.
The kinome analysis implements an array technology to measure the
enzymatic activity between whole cell lysates and protein substrates187-190.
Arrays have been assembled that contain multiple consensus sequences for a
broad range of protein kinases across the mammalian genome, allowing
detection of phosphorylation events mediated by active kinases present in whole
cell lysates. A comprehesive validation of this technology was done by evaluating
the temporal kinetics of phosphorylation events induced by lipopolysaccharide
(LPS) stimulation of human peripheral blood mononuclear cells191. Western blot
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analysis of LPS stimulated cells and peptide array studies with kinase inhibitors
demonstrated the usefulness of the technology for discovery driven signal
transduction studies191.
The recent application of advanced techniques, such as multi-color cell
sorting and the production of transgenic and gene-knockout mice, has
contributed to a better understanding of hematopoietic development from HSC to
fully differentiated cell. Now that we can purify progenitors at different
maturational stages during hematopoietic development, the challenge is to
understand the processes that govern each developmental stage. It has been
formally demonstrated that in the first few months after repopulation many
different clones can contribute to hematopoiesis, but then as repopulation is
completed and steady state hematopoiesis resumes, only a small number of
clones are needed to maintain the blood compartment134,192. The HSC clones
that prevail are considered long-term repopulating HSC (LT-HSC), whereas
clones that are present early and then subside are considered short-term
repopulating HSC (ST-HSC). Morrison and Weissman found that HSC with longterm repopulating activity could be identified in mice by the Kit+Thy1+Lin-Sca1+
(KTLS) phenotype193,194 Christensen and Weissman extended these findings to
show that such isolations could be enhanced by use of an additional marker,
Flk2195. Thus, LT-HSC could be identified based on the absence of Flk2, on the
Kit+Sca1+Flk2-Lin- subset; whereas ST-HSC acquire Flk2 while retaining the
other markers: Flk2+Kit+Lin-Sca1+. In this study, we used the phenotypes of
Christensen and Weissman to isolate both LT and ST-HSC subsets from adult
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mouse BM. Using these phenotypes we are able to obtain highly enriched HSC
populations which serve as an attractive model for array based kinome profiling.
We aim to better understand the key differences between these two cell types.
Through statistical comparisons we have discovered a list of key kinases
preferentially active in signal transduction pathways in LT and ST-HSC. In this
study we also applied kinome profiling to fully differentiated hematopoietic cells
including NK, B, T and myeloid cells to define lineage specific and basal
hematopoietic kinomes. We have then used this basal kinome to explore the
signaling differences that exist between HSC and their differentiated progeny.

Results
Our overall approach was to isolate purified cell populations, define their
phosphorylation signatures using a kinase array method, and apply statistical
methods to create comparisons between different stages of hematopoietic
development.

Purification of Cell Populations
The first step in this study was to isolate various purified hematopoietic
cell populations and generate whole cell lysates. From the spleen or bone
marrow of C57BL6/J mice, we sorted LT-HSC, ST-HSC, myeloid, T, B and NK
cells. Our method for the isolation of LT and ST-HSC was based on the KTLS
phenotypes previously described by Christensen and Weissman195. Other
differentiated hematopoietic cells were isolated based on the expression of cell
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specific receptors: B220+ for B cells, CD3+ for T cells, Mac1+ for myeloid cells
and NK1.1+CD3- for NK cells. Figure 39 shows representative FACS plots for
each of the sorted HSC populations. Three independent sorts were performed for
each cell type, consisting of a minimum of 100,000 target cells from which whole
cell lysates (WCL) were prepared.

98

Figure 39: Representative gating for hematopoietic stem cell isolation.
These dot plots show the sorting strategy for LT and ST-HSC. First mononuclear
cells are included in the isolation gate, followed by viable cells. Then viable
lineage negative cells that express cKit are included. Within this population we
gate on Sca1 and Thy1 positive cells. This Lin-cKit+Sca1+Thy1+ population is
then divided into Flk2 negative and Flk2 positive cells, representing LT and STHSC respectively.
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PepChipTM Kinome Array
Each kinome array, or PepChipTM, contained duplicate copies of 1,176
substrates. In order to measure kinase activity in the purified populations, WCL
were applied to the PepChipTM in the presence of 33P-ATP. After incubation of
the WCL with the peptide arrays, the chips are exposed to a phophor-imaging
screen. The resulting image contained 1,176 spots of varying intensity depending
on the level of phosphorylation of the individual peptide (Figure 40). Three sets of
chips were assayed from three independent isolations for each cell type, yielding
six replicate phosphorylation assays for each peptide. All raw images from the
phophor-imaging screen were analyzed using ScanAnalyze image analysis
software. With this software, the intensity of phosphorylation of each peptide was
measured and a corresponding numerical value was obtained. Using the values
from the six replicates, we were able to generate a phosphorylation signature for
each of the cell types examined.
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Figure 40: Representative replicate PepChipTM scans.
The resulting images after phosphor imaging screens are exposed to the
PepChipsTM and then developed. Two replicates for each hematopoietic cell type
are shown.
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Statistical Interpretation to Determine the Basal Hematopoietic Kinome
To create a basal hematopoietic kinome, we performed a Kruskal-Wallis
statistical analysis to determine which peptides shared a common
phosphorylation signature between B, T, NK and myeloid cells. From this
analysis we were able to determine that, of the 1,176 peptides on the kinome
chip, 492 have a common phosphorylation signature, leaving 684 peptides
differentially phosphorylated between these fully differentiated cell types. These
492 peptides, or 42%, were designated part of the basal hematokinome (Figure
41) and represent peptides that are probably involved in basal cellular processes.
Therefore, they have a lesser likelihood of yielding key differences between
different cell lineages.

Figure 41: Venn diagram demonstrating basal hematopoietic kinome.
To create a basal hematopoietic kinome, we determined which peptides shared a
common phosphorylation signature between B, T, NK and myeloid cells. The 492
peptides with a common phosphorylation signature are termed the basal
hemtokinome and represent peptides that are probably involved in basal cellular
processes.
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Differential Kinomes of LT and ST-HSC
We extended our analysis of the basal hematokinome to the
hematopoietic stem cell population. First, in order to gain insight to the functional
differences between the LT and ST-HSC populations, we compared the kinome
profiles of these two progenitor types and established a list of differentially
phosphorylated peptides through a Wilcoxon Rank Sum analysis. We then
categorized the significantly different spots based on biological function using a
bioinformatics approach. In this analysis we found that 40 peptides were
differentially regulated between LT and ST-HSC. In the design of the PepChipTM,
peptide sequences were chosen that corresponded to known or predicted
phosphorylation sites across the mammalian kinome. Therefore all sites have a
predicted protein that the peptide represents, although some overlap may exist
between proteins with similar amino acid residues. We used a protein sequence
alignment tool to cross-reference each of the 9-12 amino acid sequences to
assure we had the most accurate representation of a specific protein in mouse.
The protein with the strongest alignment was used, however in some instances
we had to take into account the actual residue being phosphorylated. We first
determined whether consensus sequences were more highly phosphorylated in
LT or ST-HSC. We then assigned a biological function for each peptide using the
human protein reference database (HPRD). Upon grouping of the functional
categories we see that ST-HSC appear to have more activity in the cell growth
pathways (Figure 42 TOP), which agrees with LT-HSC having a more quiescent
behavior (Figure 42 BOTTOM).
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Figure 42: Functional annotation for LT and ST-HSC differences.
We compared the kinome profiles of LT and ST-HSC and established a list of
differentially phosphorylated peptides. We then categorized the 40 peptides that
were differentially regulated between LT and ST-HSC based on biological
function. The top pie chart represents peptides with higher phosphorylation in
ST-HSC. The bottom pie chart represents peptides with higher phosphorylation
in LT-HSC.

104

The basal hematopoietic kinome profile was then compared to the list of
peptides significant between LT and ST-HSC specific kinomes (Figure 43). Of
the 492 basal hematopoietic kinase substrates, approximately 16 were
significantly different between LT and ST-HSC. Despite the difference in
regulation between LT and ST-HSC, these 16 kinase substrates are likely
involved in basal cellular processes and were therefore excluded from the list of
players that may be involved in key stem cell functions. In Table 3, we list the
remaining 24 peptides that were more actively phosphorylated in ‘stem’
populations and might be involved in self-renewal.
Upon grouping of the functional categories we once again see that STHSC appear to have more activity in growth and signaling (Figure 44). The
biological relevance of each of these kinases and their substrates will prove
valuable in defining molecular processes active in stem cells such as selfrenewal, long-term homeostasis and differentiation.
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Figure 43: The ‘stem’ specific kinome.
The basal hematopoietic kinome profile was subtracted from the LT and ST-HSC
specific kinomes. Of the 492 basal hematopoietic kinase substrates, only 16 are
significantly different between LT and ST-HSC. These kinase substrates are
likely involved in basal cellular processes and are therefore excluded from the list
of ‘stem’ specific signaling events.
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Table 3: Peptides sequences of proteins potentially involved in a ‘stem’
specific kinome.
Spot
306
353
313
314
354
350
551
312
365
352
320
497
339
789
802
211
438
596

Sequence
GSESTEDQA
DRRVSVAAE
ARNDSVTVA
DLFGSDEED
GGRASDYKS
PYKFPSSPLRIPGZ
GTVPSDNID
AARGSFDAS
RLSISTESQ
DAGASPVEK
SIADTFVGT
PYKFPSSPLRIPGZ
QAGMTAPGT
HKIKSGAEA
GSRRR
RRAVSELDA
QSPSSSPTH
GGVDYKNIH

420
800
807
15
22
595

LRANSI
SAYGSVKAY
SPKKSPRKA
RRAVSEQDA
QLSTSEENS
PYKFPSSPLRIPGZ

Putative
Kinase
CKII
PKA
PKA
CKII
PKA,PKC
na
GRK2,GRK5
RK
AMP-PK
PKC
na
PKC
PKC
CaM-II

PKA
PKC
sperm-specific
CaM-II
CKI
na
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Protein Name
Alpha-S1 casein
cAMP-dependent protein kinase II (PKA)
cAMP response element-binding protein CRE-BP1
elongation factor 1-beta
Myelin basic protein
unspecified protein
Beta-2 adrenergic receptor
rhodopsin kinase
phosphorylase b kinase alpha
myristolated alanine-rich C-kinase substrate
Serine/threonine-protein kinase STE7
unspecified protein
calponin alpha and beta
DNA polymerase beta
protamine
tyrosine 3-monooxygenase
phosphorylcholine transferase
Macrophage colony stimulating factor I receptor
cystic fibrosis transmembrane conductance
regulator
Annexin II
Histone H4
Tyrosine 3-monooxygenase
Alpha-S2 casein
unspecified protein

Figure 44: Functional annotation for the ‘stem’ specific kinome.
We functionally categorized the 24 peptides that were differentially regulated
between LT and ST-HSC yet not involved in basal hematopoietic cell function.
The top pie chart represents peptides with higher phosphorylation in ST-HSC.
The bottom pie chart represents peptides with higher phosphorylation in LT-HSC.
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Discussion
Unraveling the signaling pathways that control self-renewal, proliferation
and differentiation of HSC will be important for gaining an understanding of how
stem cell fate and homeostasis are controlled. Recently, similar systematic
approaches have been taken to identify gene expression patterns unique to
HSC196; however, most of the important signaling pathways that control cell
physiology rely in large part on protein phosphorylation for control. Traditional
genetic and biochemical approaches can certainly provide some of these
answers, however, for technical and practical reasons these are typically pursued
one gene or pathway at a time. Thus, a more comprehensive approach is
needed in order to reveal signaling pathways active in HSC and their
differentiated progeny. Furthermore, because HSC are rare cells, they do not
readily lend themselves to traditional biochemical methods to reveal active
signaling pathways. We have chosen to pursue an enzymatic approach that can
quantitate the phosphorylation of a wide spectrum of kinase substrates to not
only reveal kinases that are active in HSC, but also the substrates that are acted
on in HSC.
Phosphorylation forms the basis of cell signaling and can regulate almost
every property of a protein. Yet cataloging protein phosphorylation is a daunting
task as protein kinases form the single largest family of enzymes and are coded
by more than 2,000 genes197,198. Classical biochemical technologies such as
peptide mapping and phosphoamino acid analysis are extremely laborious and
often prove fruitless. In order to better tackle a problem of this magnitude,
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peptide array chips or PepChipsTM have been developed191. PepChipsTM offer a
convenient and rapid assay that requires a relatively small amount of cell lysate
to generate a large amount of data. Using this technology, we can quickly build a
broad picture of phosphorylation signatures within different cell subsets.
However, several disadvantages can slow down interpretation of the data.
The primary issue is a processing bottleneck created by the magnitude of raw
data generated199. New software tools specific for peptide arrays will help ease
this problem. When comparing expression patterns, statistical analysis can help
detect biologically relevant differences. However, frequently data points that give
statistical significance have little biological interest. Similarly, lack of statistical
significance can be a result of low sensitivity, not biological inactivity.
We have also used this novel kinase array technology to conduct a
massively parallel analysis of kinase activities. We have identified
phosphorylation signatures of LT and ST-HSC and by comparing these profiles,
we hope to determine signaling events necessary for key stem cell functions. Our
initial comparison reveals a significant degree of overlap in their respective
kinomes and we would expect to see such a high correlation. However, we
intend to examine the 3.4% difference more closely to see if it gives us some
insight into the key players involved in the step down the lineage commitment
tree that LT-HSC make to become ST-HSC. Interestingly, among these
differences we found consensus sequences matching the potent tumor
suppressor p53 were highly phosphorylated in LT-HSC. In 2007 several studies
showed that lower p53 levels in HSC corresponded with defects in stem cell
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regenerative capacity200,201. As LT-HSC differentiate into ST-HSC the
proliferation activity increases202 and self-renewal potential is believed to be
reduced. Conformingly, a recent paper showed a role for p53 in the maintenance
of HSC quiescence during steady-state hematopoiesis203. Therefore, we would
expect p53 to be differentially regulated between these populations and our
analysis validates this expectation.
Deciphering the complex network of phosphorylation-based signaling is
crucial in understanding the cells internal workings. The majority of
phosphorylation events can be considered housekeeping signaling and are
needed to keep normal cell function going. In our study we have defined the
basal hematopoietic kinome as the minimal transcriptome needed for
hematopoietic cell function. It is unlikely that these phosphorylation events
contribute to the identity of specific cell lineages. Using a systematic approach
we have attempted to identify kinase activity unique between HSC and their fully
differentiated progeny. A parallel analysis of the kinase activities of ‘fully
differentiated’ hematopoietic cells compared to HSC could help elucidate
molecular pathways involved in pluripotency and differentiation. We have
conducted peptide array analysis on B cells, T cells, myeloid cells, and NK cells.
These kinome profiles were then combined to create a ‘fully differentiated’ or
‘basal hematopoietic’ kinome. The kinases segregated into this group are
believed to be involved in normal cellular processes and were therefore deducted
from the stem cell comparison. Our initial comparison of the kinome profiles of
HSC revealed few significant differences in their respective kinomes. The
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biological relevance of the substrates with higher phosphorylation in LT-HSC
may reveal important clues as to the molecular processes that control selfrenewal and other unique stem cell properties. The functional relevance of these
differences needs to be further investigated. However we feel that this
technology provides an excellent discovery based method to identify signaling
pathways that are preferentially active in lineage commitment and stem cel
biology. This wealth of data offers a resource for further investigation of specific
proteins involved in hematopoietic differentiation.

Methods
Mice
All mice were 8-10 week old wild type C57BL6/J mice from an in-house breeding
colony or an approved vendor. On the day of cell purification the spleen and BM
were removed from sufficient animals to obtain a minimum of 250,000 pure cells.
Generally, this required 20 mice per experiment.

Purification of Cell Populations
LT and ST-HSC: BM was isolated from the legs, arms, hips and vertebrae of 20
C57BL6/J mice. A single cell suspension of BM mononuclear cells was obtained
by filtration and red blood cell lysis. Red blood cell lysis was for 5 minutes at
room temperature in a lysis buffer consisting of 0.15μM NH4Cl, 10mM KHCO3,
and 0.1mM EDTA. Cells were treated with CD16/CD32 mouse Fc block on ice for
20 minutes. Then cells were stained with a panel of Lineage specific markers
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followed by magnetic beads for enrichment using an AutoMACS (Miltenyi Biotec,
Auburn, CA). The lineage-depleted portion of the BM was then stained with HSC
specific markers, including: a lineage panel [CD2, CD3, CD4, CD5, CD8, Mac1,
Gr-1, B220, NK1.1, Ter119], Flk-2, Thy1.1, c-Kit, and Sca-1. DAPI was used for
dead cell exclusion. The LT and ST-HSC cell populations were sorted using a
FACS Aria as follows: ST-HSC were cKit+Thy1+Sca1+Flk2+Lin- and LT-HSC were
cKit+Thy1+Sca1+Flk2-Lin-. NK cells: Spleens were removed and made into a
single cell suspension by crushing, filtering and red blood cell lysis. After a 20
minute incubation with mouse Fc block, cells were stained on ice with NK1.1 and
CD3. After 15 minutes, cells were washed and resuspended for FACS. DAPI was
included for dead cell exclusion. Sorting of NK1.1+CD3- cells was performed on a
FACS Vantage (Beckton Dickson). B, T, and Myeloid cells: Similarly to NK cell
isolation, a single cell suspension of splenocytes was obtained followed by 20
minutes of mouse Fc blocking. Cells were stained on ice with markers for B220,
CD3, Gr1 and NK1.1. After 15 minutes, cells were washed and resuspended with
media containing DAPI. Mature hematopoietic cells were sorted using a FACS
Vantage. Dependent on the desired population, cells isolated were single positive
for B220+, CD3+, or Gr1+ markers. For PepChip analysis, a minimum of 100,000
cells were sorted from each cell population per experiment to obtain an
appropriate signal. After sorting, the populations were pelleted and lysed, using
an optimal kinase lysis buffer, at 500,000 cell equivalents per 50μl of buffer. The
kinase lysis buffer consisted of 20mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM
Na2EDTA, 1mM EGTA, 1% Triton X-100, 2.5mM sodium pyrophosphate, 1mM
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MgCl2, 1mM glycerophosphate, 1mM Na3VO4, 1mM NaF, 1 μg/ml leupeptin
(Sigma Aldrich), 1 μg/ml aprotinin (Sigma Aldrich), 1mM PMSF. The cell lysate
was cleared by centrifugation and flash frozen in liquid nitrogen.

Detection of Kinase Activity
Volumes of the cell lysates were equalized with autoclaved H2O. The cell
lysates were then passed through a 0.22-μm low protein binding filter. 10μL of
activation buffer was then added to the filtered cell lysates. The activation buffer
consisted of 50% glycerol, 50μM ATP, 0.05% v/v Brij-35, 0.25 mg/ml bovine
serum albumin, 33P--ATP (1000 kBq). The peptide array mix was then added to
the PepChipTM, and incubated at 37°C in a humidified chamber for 90 minutes.
The activation and cell lysate mixture phosphorylates peptide motifs spotted on
the chip. The peptide array was washed twice with Tris-buffered saline with 1%
Tween-20, then twice in 2M NaCl, and then twice in demineralized H2O and
finally air-dried. The chips were exposed to a phospho-imaging screen inside a
cassette for 72 hours. After 72 hours the phospho-imaging screens were
scanned using a Storm Phospho-imager (GE Healthcare). From the Storm
imager we obtained high-resolution image files that were imported into the
ScanAlyze software program (Lawrence Berkley National Laboratory, CA) for
analysis. ScanAlyze is an analysis software designed to process fluorescent
microarray images. To obtain median spot density a 28 X 42 grid was overlaid
onto the PepChipTM that delineated each individual peptide spot. The software
program then calculated the median spot density for each square within the grid
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thereby providing a value for the phosphorylation level for each peptide.
(Detection of kinase activity was performed with the kind help of our collaborators
Dr. Sander Diks and Dr. Maikel Peppelenbosch at the University of Groningen.)

Statistical Analysis
The median spot density for each spot on the chip was normalized across each
chip. Normalization was achieved by correction of the spot density for the
individual background to diminish inter-array variances thereby normalizing the
total phosphorylation of the chip to be equal between all samples. This helped to
compensate for differences in labeled ATP and protein levels thus facilitating
normalization between experiments. This was done by taking the
phosphorylation value for an individual spot dividing it by the sum of the total
phosphorylation of all spots on the chip and then multiplying that by the total
number of peptides (1,176). In order to be included in the kinome analysis the
mean phosphorylation between the two replicates on one PepChipTM had to have
a correlation value of greater than +0.85. Any data that was inconsistent (i.e.
SEM between data points >1.96) was excluded from further analysis. Both the
correlation and standard deviation were calculated using Excel (Microsoft,
Redmond, WA). Further statistical analyses were performed in Excel, Prism
(GraphPad, San Diego, CA), or SAS (SAS Institute, Cary, NC) with the
assistance of the Biostatistics Core Facility of H. Lee Moffitt Cancer Center. In
brief, the basal hematokinome was determined using the Kruskal-Wallis test. The
Kruskal-Wallis test is a non-parametric method to compare the equality of three
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or more population groups. It is an extension of the more commonly known
Wilcoxon Rank Sum test that applies to three or more groups. The HSC kinome
was determined using a Wicoxon Rank Sum comparison. It is a non-parametric
test used to determine whether two groups of observations come from the same
distribution. This test is used in place of a T-test when the values of the
populations being compared are not normally distributed.
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Discussion

SHIP and the BM Niche
SHIP has a significant role in regulating growth and differentiation, but
does not seem to be necessary for these processes as SHIP-/- mice are viable.
Depending on the cell type, the absence of SHIP seems to have diverse roles in
cell biology. Initial studies of HSC in SHIP-/- mice indicated an expansion of the
progenitor compartment yet impaired repopulation ability140. These data
suggested the alterations associated with SHIP-deficient HSC were
transplantable and most likely cell intrinsic. Our lab extended these findings to
demonstrate significant effects of SHIP deficiency on the ability of HSC to reach
the BM niche after transplant. The capacity of HSC to home to the right
environment is one of the essential requirements for successful repopulation of
transplanted hosts. Using a combination of in vivo homing studies and surface
receptor assessments, we determined that loss of SHIP impacts the ability of
HSC to home and lodge in the BM niche136. These studies provided additional
circumstantial evidence of a cell autonomous role for SHIP in HSC. However,
they did not address possible extrinsic influences from other SHIP-deficient cells
within the HSC BM niche.

117

Using an in situ deletion model where the BM microenvironment remains
SHIP competent, we have provided unprecedented evidence that SHIP plays a
crucial role in non-hematopoietic cells of the HSC microenvironment172. Our
results suggest that a SHIP-deficient microenvironment can deregulate the
capacity of HSC to home, lodge and engraft in the marrow space through
extrinsic influences on HSC.
The directional migration of cells via signaling molecules, also called
chemotaxis, is a key feature in the regulation of HSC homing and engraftment.
BM stromal cells and osteoblasts are believed to support and maintain stem cell
niches by interaction with HSC via various soluble factors. Specifically, the
chemokine SDF-1 is involved in trafficking HSC in and out of the BM and plays a
major role in successful HSC engraftment after transplant. Bone-lining cells
produce a gradient of SDF-1, which provides a chemo-attractant signal. In turn,
CXCR4, the receptor for SDF-1, navigates HSC through the blood to their
specialized niche in the BM. This process is tightly regulated through the
production of G-CSF, which induces the release of proteolytic enzymes such as
matrix metalloproteinase 9 (MMP-9) to inactivate SDF-1 by cleaving from its Nterminus204,205. SDF-1 degradation in turn results in the release of HSC from the
BM niche.
During hematopoietic homeostasis, most of the HSC compartment is
located within specialized niches in the BM, however a small population of HSC
are found circulating through the periphery. During situations of hematopoietic
stress mobilization occurs and the circulating population greatly increases. The
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cleavage of SDF-1 in the BM is a crucial process in breaking the anchorage of
HSC from the cells of the niche101,124,137, indicating a disruption in SDF-1
regulation could be detrimental to normal HSC homeostasis. Additionally, we
know SDF-1 dependent migration is regulated by PI3K signaling206. Both mature
and immature hematopoietic cells from SHIP-/- mice have increased chemotaxis
toward SDF-1 in vitro207. Similarly, disruption of a single PTEN allele increases
lymphocyte chemotaxis toward SDF-187. Therefore, we anticipated SHIP
deficiency might disrupt SDF-1 regulation of HSC in vivo.
Here we show that SHIP-deficient mice have significantly decreased SDF1 levels in both blood and BM. Accordingly, we see a significant increase in GCSF and MMP-9 levels in SHIP-deficient mice, which could be causing the SDF1 reduction. Furthermore, G-CSF has been shown to inhibit osteoblast activity151.
This supports our findings of a functional osteoblast impairment in SHIP-deficient
mice. A recent study by a prominent Harvard group demonstrated that
osteoblasts can directly modulate HSC function, implicating the importance of
these bone-lining cells as HSC regulators160. Additionally, osteoclasts are the
principal bone-resorbing cell and work in careful balance with osteoblasts in
maintaining bone formation. We know SHIP regulates osteoclast precursors via
the Akt pathway208. Therefore, SHIP is essential for normal bone homeostasis
and its deficiency leads to severe osteoporosis 83. Hyper-resorptive osteoclast
behavior is consistent with our findings of immature osteoblasts, which
characteristically can not support quiescent HSC160.

119

Interestingly, increased G-CSF levels also correlate with increased
reactive oxygen species (ROS)209. Accordingly, the Sharkis group has shown low
levels of ROS correspond to a quiescent osteoblastic niche210. Combined these
data suggest a requirement for the expression of SHIP for normal function of the
BM niche. SHIP-deficiency profoundly alters the BM niche, disrupting HSC
homeostasis, and causes a switch away from the quiescent osteoblastic niche.
Similar control of migration is seen in the normal development of
megakaryocytes. Once differentiation begins, megakaryocyte precursors leave
the osteoblastic BM niche and travel towards the sinusoidal vascular niche,
where they release platelets into the circulation. In SHIP-/- mice, we see a
significant increase of megakaryocytes in the spleen180, indicating the cytokine
disruption in SHIP deficiency also effects more mature hematopoietic cells.

SHIP and Peripheralized HSC
This work does not preclude SHIP from playing additional cell autonomous
roles in HSC. When SHIP is lost, a portion of the HSC compartment becomes
peripheralized. SHIP-deficient HSC mobilize to the blood and establish
hematopoiesis elsewhere rather than returning to the BM. Similarly, patients
receiving clinical G-CSF treatments to induce HSC mobilization can experience
significant enlargement of the spleen211.
Without the necessary SDF-1 signal for BM homing and retention, SHIPdeficient HSC set-up shop in a splenic niche and provide extramedullary
hematopoiesis. Consistent with this, when SHIP-deficient HSC are present, we
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consistently observe splenomegaly indicating SHIP expression is needed to
retain HSC in the BM. The down modulation of CXCR4 expression on SHIPdeficient HSC136 may also prevent recall of HSC to the BM osteoblastic
niche124,137. Interestingly, in mice where osteoblasts have been ablated, the
marrow no longer supports HSC and extramedullary hematopoiesis occurs212.
In myeloid cells, SHIP functions to limit proliferation and PI(3,4,5)P3
production, which in turn regulates the activation of the serine/threonine kinase
Akt60. Additionally, SHIP can control growth factor induced PI(3,4,5)P3 and Akt
activation in mast cells, B cells26, and neutrophils213. Consistent with this, SHIPdeficient mature hematopoietic cells exhibit elevated Akt levels and have an
increased resistance to apoptosis. This was shown to be mediated through PI3K
signaling using a potent inhibitor, wortmannin, which prevents PI(3,4,5)P3 from
accumulating36.
Here we show that SHIP has a critical responsibility in regulating PI3K
signaling in HSC, thereby controlling anti-apoptotic/survival signals. It is
important to note that the phospholipid regulation of Akt is complex and that Akt
can interact with both PI(3,4,5)P3 and PI(3,4)P2214. Recent studies indicate the
accumulation of PI(3,4,5)P3 is associated with Threonine 308 phosphorylation of
Akt, whereas PI(3,4)P2 levels correspond with Serine 473 phosphorylation of
Akt215. We have only seen evidence of increased Threonine 308 phosphorylation;
however, it seems plausible that perturbation of several independent pathways
could contribute to the ability of SHIP-deficient HSC to survive in environments
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that are inhospitable for SHIP-competent HSC. Ultimately, we show that
extramedullary SHIP-deficient HSC possess normal HSC activity.
Combined, these studies suggest SHIP expression is required to support
normal HSC function in the BM niche; however, in the absence of SHIP normal
HSC function is transferred to the periphery. Differential responsiveness to
cytokines between BM and spleen derived HSC has previously been reported216.
In embryogenesis, we see evidence of successive anatomical niches supporting
different HSC functions, we speculate then that a peripheral HSC niche may exist
in the spleen of SHIP-deficient animals. HSC located in this splenic niche have
normal HSC function and can respond normally to chemokine signals after
transplant. It will be interesting to examine CXCR4 surface expression on HSC
isolated from SHIP-/- spleens, since it appears the splenic niche does not alter
homing capacity of HSC like the SHIP-/- BM niche does.
Recent studies have begun to focus on the complex role of the niche in
HSC regulation. One group has even generated a functionally supportive HSC
niche within an ectopic site217. This supports our hypothesis of the existence of
HSC niches in tissues outside the BM, such as the spleen. These types of
studies will help elucidate a functional understanding of the niche.
We already know that when BM hematopoiesis is impaired by cancer or
myeloablation, increased numbers of HSC can engage in hematopoiesis in the
spleen. Therefore, it seems logical that a SHIP inhibition strategy could prove
useful in temporarily relocating functional hematopoiesis to the spleen in hopes
of rescuing hematopoiesis in settings of BM failure. There is certainly a concerted
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effort to develop small molecule inhibitors of SHIP to temporarily render it
inactive.
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Scientific Significance

Inositol Phospholopid Signaling and Cancer
Cancer develops when the balance between new cell generation and cell
death is lost. Therefore, the activation of survival signaling must be tightly
regulated. In fact, evasion of apoptosis is considered to be a hallmark of cancer,
because loss of apoptosis regulation invariably leads to tumorigenesis218.
For over 20 years the PI3K pathway has been a focus in the cancer
research field. Several components of the PI3K pathway, such as PTEN, are
dysregulated in a wide spectrum of cancers. Inactivation of PTEN in BM HSC
causes their rapid expansion followed by long-term decline165. Normal HSC
become depleted and are replaced by leukemia initiating cells or cancer stem
cells165,166. In humans, loss of PTEN function usually results in a
myeloproliferative disorder and eventually leukemia166. Unlike PTEN, there is no
explicit role for SHIP as a tumor suppressor. In fact, there is very little evidence
that SHIP mutations are present in human cancers. A specific role for SHIP
mutation in diseases appears limited to myeloproliferative disorders81 and
osteoporosis83. However, a Belgian group recently showed that SHIP has an
important role in leukemic cell responses to ROS in terms of apoptosis
resistance219. Both SHIP and SHIP2 have been shown to be constitutively
phosphorylated and associated with Shc in leukemia progentitor cells35. Another
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group discovered an inactivating mutation in the catalytic domain of SHIP within
the blast cells of a patient with acute myelogenous leukemia (AML)220. However
these findings are very preliminary and there is still no statistical evidence of a
role for SHIP in leukemia.
The balance of HSC homeostasis is achieved by integrating a combination
of external cues and intrinsic molecular signals. Understanding the molecular
signaling relationship between self-renewal, proliferation and functional
commitment is important to harnessing the full clinical potential of HSC. If we can
determine key phosphorylation events responsible for influencing HSC fate
choices, we can likely reveal the signaling pathways that underlie these events.
Our kinome results demonstrate the ability of peptide arrays to enhance
our understanding of phosphorylation dependent signaling. This may give some
understanding of the molecular changes that occur when an HSC undergoes
lineage commitment and becomes irreversibly locked in its fate. However,
generating pathways from lists of phosphorylated sequences will require linking
these events with downstream signaling. Integration of extensive bioinformatics
and improved statistical analysis is likely to improve the value of this data. Initial
data from this study is promising, but array based technology provides a useful
starting point and concrete validation will be required.
Not only is there a high therapeutic value in gaining a better understanding
of HSC signaling, there are many other clinical applications for this technology.
Tyrosine kinase activity is frequently deregulated in cancer and can drive tumor
cells to proliferate inappropriately. By identifying the kinases involved in disrupted
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signaling regulation, we can develop more effective cancer treatments. Since
cancer cells share many functional properties with normal stem cells, it is crucial
to understand the molecular signaling pathways involved in these properties. We
need to identify ways to therapeutically target pathways that differentially impact
the self-renewal of HSC and cancer cells. Implementing array based kinome
technology could provide rapid elucidation of key differences.

Cancer Stem Cells
A selective growth advantage by cancer cells rapidly led to comparisons
with somatic stem cells. Both cell types have self-renewal properties and can
differentiate into heterogeneous populations. John Dick was first to describe the
existence of “cancer stem cells” in 1994 in AML221,222. Since then, much work has
surrounded the cancer stem cell hypothesis165,223-225, which claims that there
should be mechanistic similarities between the self-renewal and hierarchical
differentiation of stem cells and cancer cells226.
The question of whether a fraction of cancer stem cells have self-renewal
potential has fundamental clinical implications, as cancer stem cells might be
more resistant to chemotherapy than non-tumorogenic cancer cells. The
evidence for cancer stem cells in leukemia remains convincing, however a recent
publication challenges the cancer stem cell hypothesis in solid tumor models227.
This study challenges the idea of a rare population within the tumor cells that can
self-renew to continually regenerate cancer. When melanoma cells were
transplanted into NOD/SCID mice lacking the IL-2 gamma receptor, as many as
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one in four cells could generate a tumor, indicating self-renewing/tumorogenic
cancer cells are not a rare event227. So is a cancer stem cell just a cancer cell?
Critics of this work suggest that self-renewing cells don’t need to be rare to be
worthy of attention. Furthermore, perhaps most melanoma cells possess selfrenewal up to a certain limit but only a few will persist. Regardless of the
terminology used to describe these tumorogenic cells, the fact remains that a
better understanding of the signaling and environment needed for self-renewal
will help establish improved cancer treatments.
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